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Diabetes is one of America’s leading chronic diseases with comorbidities contributing to 
lower health statuses and increased health care costs. While it is known that lowering 
HbA1c reduces the deleterious effects of diabetes, the capability to identify people with 
diabetes at risk for uncontrolled HbA1c levels or developing comorbidities based on the 
compliance rates for different oral antihyperglycemic medication classes (OAMCs) and 
financial assistance programs does not yet exist.  These quantitative longitudinal 
retrospective studies examined the association between  medication compliance, using 
Proportion of Days Covered (PDC), by OAMC and Medicare financial aid programs, on 
predicting HbA1c levels and comorbidities in type 2 diabetics. Jaam’s medication 
compliance framework guided sample selection from the 2019 claims database of a large 
Managed Care Organization with limited eligibility of only 60% of the population which 
had an HbA1c level checked in the past 12 months. Multiple regression analyses revealed 
that as compliance rates improve, different OAMC combinations are associated with 
significant and variable reductions in A1c levels but with minimal effect strengths not 
allowing the linear regression model to be used as a predictive tool.  Financial assistance 
programs have a small, but statistically significant effect on reducing HbA1c levels, 
comorbidities, or improving compliance rates. These studies are the first to investigate 
the association between PDC compliance rates for OAMCs on HbA1c and comorbidities.  
These findings contribute to positive social change by demonstrating that variable patient 
compliance rates for different OAMC medication classes and HbA1c testing should be 
considered when prescribing diabetic therapeutic regimens to achieve optimal HbA1c 
control and improved health status.  
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Part 1: Overview  
Introduction 
Purpose for Study 
Diabetes ranks seventh in the cause of death in the US, with 122 million 
Americans actively diagnosed with diabetes or prediabetes; almost one-third of the US 
population. Diabetes cases surged between 2008 and 2018 with the incidence highest in 
Native Americans and Alaskan Indians. One third of people with diabetes have chronic 
kidney disease and fewer than 25% are aware they suffer from this comorbidity. 
Currently rates in those aged 10-19 have increased significantly. Only 50% of diabetics 
have their HbA1c levels under control at less than 7% (Centers for Disease Control and 
Prevention, 2020). One out of every four dollars spent on healthcare in the US is related 
to diabetes (Riddle & Herman, 2018).  Additionally, diabetes comorbidities, including 
Myocardial infarction, End-Stage Renal Disease, Blindness, and Urinary Tract Infections 
create additional financial burdens through reduced health statuses. Medication 
compliance is a crucial part of any diabetes treatment plan, yet people with diabetes 
remain non-compliant in taking their medications. Diabetes is the most expensive chronic 
disease to treat, primarily due to the high comorbidity rates and complications.   
In 2008, Medicare (CMS) implemented a quality rating system for many 
healthcare providers, called the Star Score Ratings, ranging from one to five with one 
being a poor rating and five being the highest rating possible. This ranking system 





providers (Cotton et al., 2016). In 2017, state Medicaid programs adopted a quality rating 
system called the Medicaid Health Plan Rating System, or HPR, created by the National 
Center for Quality Assurance (NCQA) (National Center for Quality Assurance, 2018b). 
Under Medicare, Managed Care Organizations (MCO) face a 9% loss in payments low 
quality ratings and a 9% bonus payment for a high quality rating with payment in the 
form of bonuses and rebates.  
NCQA diabetes measures are part of the Healthcare Effectiveness Data and 
Information Set, better known as the HEDIS system, based on six domains of care 
(National Center for Quality Assurance, 2018a). Diabetes falls under the chronic 
conditions domain and includes measures of HbA1c control, annual retinopathy and 
nephropathy screening compliance, and controlled blood pressure. Because of the 
financial risk that healthcare organizations face if they do not meet their CMS or HPR 
HEDIS standards for people with diabetes, there is a need for analytic tools to help these 
organizations identify those at risk for high HbA1c levels and minimize the comorbidities 
of diabetes.  
Theoretical and Practical Relevance 
Jaam’s Diabetes Medication Compliance Framework 
With over forty years of studies on medication compliance, current frameworks 
are still fragmented (Allemann et al., 2016). In 2018, Jaam et al., developed a framework 
defining the relationship between the HEDIS CDC diabetes measure and medication 





predictors included are type of diabetes, HbA1c level, comorbidities, glucose control, 
duration of diabetes, diabetes-related factors, and classes of blood sugar control 
medications taken. The Social Determinants of Health (SDOH) factors such as insurance 
type, demographics and health literacy, are included as predictors in the studies presented 
here. All these predictors are part of Jaam’s framework shown in Figure 1. 
Figure 1  
Medication Compliance Framework  
 
Medication Adherence 





Social Determinant of 
Health (SDOH) factors 










Taken from Jaam’s Medication Compliance Framework Jaam et al. (2018) 
Current Scientific Understanding 
In 2015, diabetes was the seventh leading cause of death in the US. 
Approximately 117 million Americans have either diabetes or prediabetes, constituting 
almost one-third of the US population. Other disturbing factors related to diabetes include 
only one in four people with diabetes know they have the disease, in 2015 there were 1.5 
million new diagnoses in those over 18, more men are diagnosed as prediabetic than 
women, and diabetes contributes to other diseases such as cardiovascular, stroke, 
neuropathies, and kidney disease (Center for Disease Control, 2017). 
Healthcare organizations are interested in diabetes because of the financial 
challenges presented by quality measures introduced by Medicare. The NCQA HEDIS  
measures are used to evaluate the quality of care for 190 million individuals, or 60% of 
the US population (National Committee for Quality Assurance, 2018a). HEDIS measure 
compliance is part of the calculation of base financial rewards or penalties based on how 
well providers perform against NCQA standards. Penalties for Medicare Advantage plans 
not meeting quality goals can see reduced payment rates and bonus money loss. Penalties 
for Medicaid MCO’s are set by individual states using the HPR system established by the 
NCQA. Penalties for not meeting quality standards include payment holdbacks, changes 






 With one-third of the US population having some form of diabetes and the 
financial penalties for MCO’s not reaching set quality scores, MCO’s need help 
identifying those at risk for uncontrolled HbA1c levels, high rates of medication non-
compliance, and for not meeting HEDIS quality standards. The studies in this dissertation 
focus on developing and validating methods to help MCO’s identify people with diabetes 
that may contribute to low-quality scores, examine the effectiveness of two Medicare 
financial subsidy programs, and examine the relationship between medication compliance 
and medication class and four of the comorbidities of diabetes. 
Scope and Delimitations 
The goal of these studies is to show that the Proportion of Days Covered (PDC), a 
medication adherence measurement methodology, for individual antihyperglycemic 
medications class being taken, and participation in financial assistance programs, can be 
used in multiple regressions as a method to identify at-risk individuals for uncontrolled 
HbA1c levels and those at risk for the comorbidities of diabetes. If these proposed 
analysis are found valid, they give organizations a quick and proactive way to improve 
their HEDIS diabetes compliance rates and reduce their financial risks. While there are 
studies in the literature discussing the HEDIS PDC measure, there are none on its use 
combined with a class of antihyperglycemic medication as a predictor for HbA1c levels. 
This study presents an opportunity to fill a gap in the literature that, to date, has not been 





Participants for these studies were selected using secondary claims data provided by a 
large MCO.  
Problem Statement 
Healthcare organizations that must comply with the HEDIS standards face both 
financial and human issues. First, there are financial penalties for not meeting the quality 
standards set by Medicare and Medicaid. Second, MCO’s face additional medical costs 
created by their members who do not comply with quality standards. The first manuscript 
establishes a relationship between medication compliance and six of the nine classes of 
oral antihyperglycemic medications and HbA1c levels. The second study establishes the 
statistical significance of the relationship between the two Medicare financial subsidy 
programs, Low Income Subsidy (LIS) and Dually Eligible Special Needs Program 
(DSNP) on HbA1c levels and medication compliance in any of the six classes of oral 
antihyperglycemic medications, there is not any significant strength of effect.. The third 
manuscript identifies some statistically significant factors for those at risk for four of the 
comorbidities of diabetes, blindness, end-stage renal disease, myocardial infarction, or 
urinary tract infection based on medication compliance, the class of antihyperglycemic 
medication taken, and HbA1c levels.  
Health care systems have a vested interest in maintaining a high health status for 
all members because of the shift to value and quality-based contracting. Essentially, the 
healthier an MCO can keep its members, the higher the financial rewards available from 





paying attention to their health. Many health care systems face high costs from people 
with type 2 diabetes, primarily due to the disease's complications (Dall et al., 2014). 
Medication compliance plays a vital role in diabetes management with low medication 
compliance rates and reduced health status leading to suboptimal therapeutic outcomes in 
people with diabetes that plays a role in their reduced health statuses (Huang et al., 2018; 
Polonsky & Henry, 2016).   
Research question/hypothesis for each manuscript 
The first two manuscripts examine how medication compliance in six of the 
classes of antihyperglycemic medications and Medicare financial subsidy programs and 
various covariates such as age, sex, deductible, number of hospital visits, seeing an 
endocrinologist, participation in renal and retinal screenings, having a diagnosis of 
blindness, myocardial infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP 
enrollment, and controlled blood pressure (Feingold, 2019). Manuscript three looks at the 
relationship between HbA1c levels, antihyperglycemic medication class, and medication 
compliance on blindness, urinary tract infections, end-stage renal disease, and myocardial 
infarction. The relationships presented in the first two studies provide evidence for 
practitioners treating this diabetes. Study three established that the PDC, HbA1c levels 
are a predictors four of the comorbidities of diabetes.   
In the first manuscript, we investigate the PDC for participants only taking one of 
the antihyperglycemic medication classes during the year.  Because we only have a single 





classes to a change in a single HbA1c level. The outcome variable, HbA1c levels, is 
continuous, and therefore, multiple regression analyses were performed on this data. This 
manuscript's title is "Medication Compliance by Drug Class as a Predictor of HbA1c 
Values in Medicare Type 2 Diabetics". The research questions for this manuscript are: 
RQ1: What is the relationship between the PDC and the antihyperglycemic class of 
medication on HbA1c in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in renal and 
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure?  
H01: There is no statistically significant relationship between the PDC and the 
Biguanides class of medications on HbA1c in Medicare type 2 diabetics while 
controlling for age, sex, deductible, number of hospital visits, seeing an 
endocrinologist, participation in renal and retinal screenings, having a diagnosis 
of blindness, myocardial infarction, UTI, end-stage renal disease, LIS enrollment, 
DSNP enrollment, and controlled blood pressure?  
H11: There is a statistically significant relationship between the PDC and the 
Biguanides class of medications and HbA1c values in Medicare type 2 diabetics 
while controlling for age, sex, deductible, number of hospital visits, seeing an 
endocrinologist, participation in renal and retinal screenings, having a diagnosis 
of blindness, myocardial infarction, UTI, end stage renal disease, LIS enrollment, 





H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H12: There is a statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 





hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H03: There is no statistically significant relationship between the PDC and the 
Thiazolidinedione class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H13: There is a statistically significant relationship between the PDC and the 
Thiazolidinedione class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure.  
H04: There is no statistically significant relationship between the PDC and the 
Sulfonylureas class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 





H14: There is a statistically significant relationship between the PDC and the 
Sulfonylureas class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure.  
H05: There is no statistically significant relationship between the PDC and the 
Meglitinide Analogues class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H15: There is a statistically significant relationship between the PDC and the 
individual Meglitinide Analogues class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H06: There is no statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and 





deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, end stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure. 
H16: There is a statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure. 
RQ2:   What is the relationship between PDC and combinations of antihyperglycemic 
class of medications and HbA1c values in Medicare type 2 diabetics while controlling for 
age, sex, deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, 
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure? 
H07: There is no statistically significant relationship between the PDC and the 
Meglitinide-Biguanide Combinations class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 





screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure.  
H17: There is a statistically significant relationship between the PDC and the 
Meglitinide-Biguanide Combinations class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure. 
H08: There is no statistically significant relationship between the PDC and the 
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure.  
H18: There is a statistically significant relationship between the PDC and the 
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 





infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure.  
H09: There is no statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure. 
H19: There is a statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, end-stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure. 
H010: There is no statistically significant relationship between the PDC and the 
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type 
2 diabetics while controlling for age, sex, deductible, number of hospital visits, 





diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H110: There is a statistically significant relationship between the PDC and the 
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type 
2 diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H011: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c 
values in Medicare type 2 diabetics while controlling for age, sex, deductible, 
number of hospital visits, seeing an endocrinologist, participation in renal and 
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, 
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H111: There is a statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c 
values in Medicare type 2 diabetics while controlling for age, sex, deductible, 
number of hospital visits, seeing an endocrinologist, participation in renal and 





end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H012: There is no statistically significant relationship between the PDC and the 
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure. 
H112: There is a statistically significant relationship between the PDC and the 
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, end-stage 
renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure. 
Manuscript two examines participation in Medicare financial assistance programs 
as an indicator of income and assets and oral antihyperglycemic medication PDC, while 
controlling for covariates, to see if they can successfully predict HbA1c levels. Medicare 
sets income levels for participation in the LIS and DSNP programs, and these programs 
are mutually exclusive in that an individual can only be in one at a time.  Participants are 
those not in a subsidy program, those in a LIS program, and those in a DSNP program. 





selection criteria. Linear regression analysis were used to develop our model with HbA1c 
as a continuous outcome variable. This manuscript's title is "Dually Eligible, Low-
Income Subsidy Enrollment, and Medication Compliance as Predictors of HbA1c in Type 
2 Diabetics". The research questions for this manuscript are: 
RQ3: What is the relationship between enrollment in a LIS program, DSNP enrollment, 
oral antihyperglycemic medication class, PDC, and HbA1c levels in Managed Care 
enrollees with type 2 diabetes while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, and living in Urban or Rural County?   
H013: There is no statistically significant relationship between enrollment in a LIS 
program, oral antihyperglycemic medication class, PDC, and HbA1c levels in 
Managed Care enrollees with type 2 diabetes while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, and living in Urban or 
Rural County. 
H113: There is a statistically significant relationship between enrollment in a LIS 
program, oral antihyperglycemic medication class, PDC, and HbA1c levels in 
Managed Care enrollees with type 2 diabetes while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, and living in Urban or 
Rural County. 
H014: There is no statistically significant relationship between enrollment in 
DSNP program, oral antihyperglycemic medication class, PDC, and HbA1c levels 





diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County. 
H114: There is a statistically significant relationship between enrollment in a 
DSNP program, oral antihyperglycemic medication class, PDC, and HbA1c levels 
in Medicare type 2 enrollees with diabetes while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County. 
H015: There is no statistically significant relationship between enrollment in LIS 
and DSNP programs, oral antihyperglycemic medication class, PDC, and the and 
HbA1c levels in Managed Care enrollees with type 2 diabetes while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living 
in Urban or Rural County.  
H115: There is a statistically significant relationship between enrollment in LIS 
and DSNP programs, oral antihyperglycemic medication class, PDC, and the and 
HbA1c levels in Managed Care enrollees with type 2 diabetes while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living 
in Urban or Rural County. 
Manuscript three analyzes oral antihyperglycemic medication class compliance in 
the six classes of antihyperglycemic medications, HbA1c levels, and whether they can be 
used to predict any of the comorbidities or combinations of comorbidities Managed Care 





one class of antihyperglycemic medication during the year. The data as analyzed using 
logistic regression because our outcome variables, comorbidity, or sets of comorbidities, 
are binary. This manuscript's title is "Medication Compliance, HbA1c Predicting 
Comorbidities in Medicare Type 2 Diabetics". The research questions for this manuscript 
are: 
RQ4: What is the relationship between the PDC calculated for individual 
antihyperglycemic class of medications and HbA1c values and the top four type 2 
diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, 
and Urinary Tract infections, both individually and in combination, in Medicare enrollees 
with type 2 diabetes while controlling for age, sex, diabetes diagnosis time, length of time 
in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County as defined by the Census Bureau. 
H016: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the top 
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness, 
End-Stage Renal Disease, and Urinary Tract infections while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H116: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the top 





End-Stage Renal Disease, and Urinary Tract infections while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County.  
H017: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of 
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 
infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H117: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of 
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 
infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County.  
H018: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H118: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County.  
H019: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylureas class of medications and the top four Medicare 
type 2 diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage 
Renal Disease, and Urinary Tract infections and HbA1c values while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H119: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylureas class of medications and HbA1c values and the 
top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 





H020: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H120: There is a statistically significant relationship between the PDC index 
calculated for the individual Meglitinide Analogues class of medications and 
HbA1c values and the top Medicare four type 2 diabetes comorbidities of 
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 
infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County.  
H021: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the top four Medicare type 2 diabetes 
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and 
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 





H121: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the top four Medicare type 2 diabetes 
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and 
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County.  
H022: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Myocardial Infarction and HbA1c while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H122: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Myocardial Infarction while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H023: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial 





MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H123: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial 
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H024: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H124: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H025: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H125: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and the comorbidity of 
Myocardial Infarction and HbA1c values in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H026: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Myocardial Infarction in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H126: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Myocardial Infarction in type 2 diabetics while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H027: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Myocardial Infarction in 





length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H127: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Myocardial Infarction in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H028: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H128: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H029: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 





while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H129: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H030: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H130: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H031: There is no statistically significant relationship between the PDC index 





Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H131: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H032: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of Blindness while controlling for 
age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H132: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Blindness in Medicare type 2 diabetics while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H033: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 





type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H133: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Blindness in Medicare 
type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H034: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H134: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H035: There is no statistically significant relationship between the PDC index 





and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage 
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H135: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage 
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H036: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H136: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 





H037: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H137: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H038: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H138: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of End-Stage Renal Disease in Medicare type 2 diabetics 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 






H039: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of End-Stage Renal Disease 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and 
living in Urban or Rural County. 
H139: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of End-Stage Renal Disease 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and 
living in Urban or Rural County. 
H040: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H140: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H041: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract 
Infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H141: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract 
Infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H042: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H142: There is a statistically significant relationship between the PDC index 





the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H043: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H144: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H045: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H145: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 





while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H046: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Urinary Tract Infections in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H146: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Urinary Tract Infections in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
Outline of Dissertation 
Introduction 
With the introduction of quality standards for health care organizations and the 
financial penalties associated with not attaining established levels of quality, the need for 
appropriate regression analysis for MCO’s has increased. The first study determines the 





medications, in identifying those at risk for high HbA1c levels. Having regression 
analysis available helps healthcare organizations proactively work with people with 
diabetes who are a risk for high HbA1c levels. The second study in this dissertation 
establishes that the PDC, calculated for individual antihyperglycemic medications, and 
participation in Medicare financial assistance programs can be used to identify 
individuals at risk for high HbA1c levels. The third study in this dissertation uses logistic 
regression analysis with diabetes comorbidities as outcome variables and individual 
HbA1c levels, PDC medication compliance rates, antihyperglycemic medication classes, 
and various covariates as predictors.  
Social change 
Diabetes is a chronic disease that impacts more than one-third of Americans 
(American Diabetes Association, 2018d). Medication compliance in people with diabetes 
is essential for keeping HbA1c levels under control, and many people with diabetes have 
issues with compliance (Kennedy-Martin et al., 2017). Medicare created several financial 
subsidy programs covering medication copays and deductibles with one goal of 
improving medication compliance.  Diabetes comorbidities further complicate dealing 
with these individuals. Quality standards for diabetes that many healthcare organizations 
must meet complicate the already tricky scenario of managing diabetes. Using the 
Medicare PDC calculated for individual antihyperglycemic medications as a predictor of 
HbA1c levels, predicting comorbidities of diabetes, and evaluating the effectiveness that 







Review of Diabetes 
 Diabetes refers to a group of diseases related to a defect in the body’s ability to 
utilize glucose properly. In the US, 35 million people have been diagnosed with diabetics, 
7 million have undiagnosed diabetes, while another 88 million have prediabetes (Centers 
for Disease Control and Prevention, 2020). Many people are undiagnosed and unaware 
that they are at risk for developing diabetes (National Institute of Diabetes and Digestive 
and Kidney Diseases, 2017). Diabetes-related health expenditures increased from $245 
billion in 2012 to $345 billion in 2017, one dollar out of every four spent on healthcare in 
the US (Riddle & Herman, 2018).   
 Diabetes can lead to multiple complications, including heart disease, stroke, 
nephropathies, retinopathies, dental problems, and neuropathies (National Institute of 
Diabetes and Digestive and Kidney Diseases, 2018). In 2013, diabetes was the seventh 
leading cause of death in the US, a total that could be underreported. Twenty percent of 
all healthcare expenditures are for the treatment of diabetes or any one of its 
complications (National Center for Chronic Disease Prevention, 2016).  
 The American Diabetes Association established a Professional Practices 
Committee that developed and annually updates a “Standards of Medical Care in 
Diabetes.”  The group comprises physicians, educators, dieticians, and others with 





The standards' recommendations are evidence-based, developed through collaboration, 
aligned with the Chronic Care Model, and support improvements in quality of care 
through quality improvement strategies. These standards address the Social Determinants 
of Health and their role in diabetes (American Diabetes Association, 2018c).  
For many years, the standard test for determining a diagnosis of diabetes was a 
glucose tolerance test. However, in 2006, the World Health Organization recommended 
using the HbA1c, a glycosylated form of hemoglobin, with a measure that indicates 
glucose levels for several months. Reported studies use the continuous HbA1c value, 
including self-efficacy, medication compliance and health literacy, and a longitudinal 
study in the UK that looked at estimating future HbA1c levels (Huang et al., 2018; 
Sheppard et al., 2017). In 2011, the ADA recommended an HbA1c value of greater than 
6.5% for a diagnosis of Diabetes and have included it as part of their standards (Malkani 
& Mordes, 2011; World Health Organization, 2006).  
Type 2 diabetes is the most expensive of all the chronic diseases for many 
healthcare systems, primarily due to the disease's high rate of complications (Dall et al., 
2014). This cost burden is continuing to grow (Seuring et al., 2015). To complicate this 
issue, only 50% of individuals on medications for diabetes fail to achieve adequate blood 
sugar control or attain an HbA1c level of less than 7% (Centers for Disease Control and 
Prevention, 2020; Polonsky & Henry, 2016).  





There are several types of diabetes. Chronic diabetes includes type one, or insulin-
dependent, and type two, generally treated with oral medications. There are other types of 
diabetes, including gestational, that occurs during pregnancy, cystic fibrosis-related 
diabetes, and monogenic or genetically related diabetes. A blood test diagnoses diabetes, 
looking at fasting glucose levels greater than 120 mg/dl or HbA1c levels greater than 
6.5% in all of these forms of diabetes.  
Type one diabetes, generally diagnosed in children and young adults, is also 
known as juvenile diabetes but can present at any age. It occurs in approximately five 
percent of the population and has no regard for body size, ethnicity, or age. In type one 
diabetes, the body does not produce any insulin and, as a result, has no way to get glucose 
from the blood into the cells (American Diabetes Association, 2019). 
Type two diabetes is the most common form and comes from the body's inability 
to utilize insulin properly. It appears at any age, but most often in adults (National 
Institute of Diabetes and Digestive and Kidney Diseases, 2016b).  Type two diabetes 
forms slowly, and its onset can be delayed by lifestyle changes such as weight loss or diet 
change. In diabetes early stages, the body secretes additional amounts of insulin to make 
up for its inability to use it, a condition called insulin resistance. Over time, the pancreas 
cannot produce enough insulin and either oral medication or insulin is instituted. The 
health status of people with type two diabetes generally worsens over time. The 
symptoms of type two diabetes include thirst, frequent urination, feeling hungry or tired, 







Individuals with a fasting glucose level above 110 mg/dl to 125 mg/dl and a two-
hour glucose tolerance test level of 140 – 200 mg/dl are at risk of developing type 2 
diabetes, a condition known as prediabetes. The American Diabetes Association further 
refined the definition of prediabetes to include an HbA1c level between 5.7% – 6.4% 
(Bansal, 2015). However, there is some controversy about the value of using HbA1c 
levels to make a diagnosis of prediabetes, with the best diagnostic tool being a two-hour 
fasting glucose tolerance test (Maki, 2017). Approximately 10% of prediabetics convert 
to diabetics each year (Knowler et al., 2002).  Prediabetes puts patients at risk for type 2 
diabetes, heart disease, and stroke. Predictors of prediabetes include being overweight, 
older than 45, have a parent or sibling with type 2 diabetes, low physical activity, a 
previous diagnosis of gestational diabetes, or are African American, Native American, 
Latino, or Asian American.  
Just because an individual is diagnosed with prediabetes does not mean that they 
will transition to diabetes. Changing dietary habits, increasing physical activity, and 
reducing stress are all shown to delay or prevent a diagnosis of prediabetes (Centers for 
Disease Control and Prevention, 2018b).  
The association between prediabetes and macrovascular disease is well 
established (H. Hu et al., 2018). Prediabetes in adolescents leads to obesity, high 
cholesterol levels, low levels of HDL cholesterol, and elevated liver transaminase 





cardiovascular disease (ASCVD) is twice that in prediabetics, and elevated lipoprotein(a) 
is more common in prediabetic Caucasians than in African Americans (Saeed et al., 
2019).  
Microvascular risks from prediabetics include renal, retinal, and peripheral 
problems. The exact mechanism of these complications is unknown, but the metabolic 
changes associated with diabetes cause oxidative stresses, inflammation, and vascular 
occlusion (Safi et al., 2014). However, these injuries take years to develop with 
uncontrolled glucose levels. Therefore, active efforts to change diet and lifestyle can 
eliminate or delay the onset of these complications (Brannick et al., 2016).  
Prediabetes presents with the same cardiovascular (macrovascular), renal, retinal, 
and peripheral nerve (microvascular) damage potential as in people with diabetes, just at 
a lower rate. When a patient is diagnosed with prediabetes, it does not necessarily foretell 
future diabetes. Diabetes can be stalled or prevented by making lifestyle and dietary 
changes. Patients who avoid the progression of prediabetes to diabetes can reduce their 
overall healthcare costs, improve their health status and quality of life (Carris et al., 
2019). 
Measurement 
Blood glucose monitoring is the foundation of diabetes and prediabetes treatment. 
Blood glucose level was the traditional method for diagnosing diabetes before accepting 
the HbA1c level as a viable measure. Any level over 99 mg/dl is considered pre-diabetes. 





(National Institute of Diabetes and Digestive and Kidney Diseases, 2016a).  In 2011, the 
ADA endorsed the use of the HbA1c level (Malkani & Mordes, 2011). The advantage of 
HbA1c is that it indicates how high the blood sugar level reached over the last two to 
three months, based on the lifetime of the red blood cell holding the glucose (Medline 
Plus, 2018).   
HbA1c was first identified in 1958 and identified as a glycoprotein in 1968. In 
1969 elevated HbA1c levels were found in diabetics and was first proposed in 1976 as an 
identifier of diabetes (Bookchin & Gallop, 1968; Huisman et al., 1958; Koenig et al., 
1976; Rahbar et al., 1969). Clinically accepted normal levels of HbA1c are below 5.7%, 
prediabetes levels are between 5.7% and 6.4%, and diabetes is diagnosed at levels above 
6.5% (American Diabetes Association, n.d.).  
Blood sugar measurement falls into several categories, invasive and non-invasive 
and intermittent and continuous. Invasive techniques are those where a sensor is 
implanted into the body and has some means for transmitting glucose levels to an 
external monitoring system. Finger prick systems are considered an invasive method and 
are the most common measuring method in use.  Non-invasive systems are those where 
there is no body implantation of sensors to determine glucose levels. Continuous systems 
can consistently monitor glucose levels over time, and with intermittent systems, HbA1c 
levels are determined at various points in time.  
The most common invasive method of monitoring glucose levels is using a 





invasive methods, a drop of blood is applied to a test strip inserted into a device 
displaying the amount of glucose present in the sample. These electronic devices must be 
recalibrated with each new packet of measurement sticks. Failure to do so can introduce 
errors of up to 50 mg/dl. Low health literacy may affect these measurements' accuracy 
due to numeracy issues (Ginsberg, 2009; Jun, 2019). Continuous monitoring is generally 
reserved for those with type 1 diabetes.  
Complications of Diabetes 
Primary complications of diabetes come from the micro and macrovascular co-
morbidities associated with diabetes. The complications include diabetic retinopathy, 
nephropathies, neuropathies, and atherosclerosis.  Diabetes is a predictor of stroke and 
cardiovascular disease (Fowler, 2008). Approximately one-third of the 285 million 
diabetics worldwide suffer from diabetic retinopathy, which is the leading cause of vision 
loss in adults 20 – 74 years old (Yau et al., 2012). Diabetic retinopathy contributes to 
other diabetes complications, including nephropathy, cardiovascular events, and 
peripheral neuropathies.  
Diabetic neuropathies can be asymptomatic and are not exclusively related to 
diabetes. Because the nerve damage from diabetic neuropathies cannot be reversed, the 
best plan is prevention (Bourne et al., 2013; Pop-Busui et al., 2017). Diabetic 
neuropathies can be non-painful, making patient recognition difficult if they do not 
perform regular body checks (Hägg et al., 2013; He et al., 2013; Mottl et al., 2014). The 





Diabetic Association recommends the use of low-density lipoprotein (LDL) and 
cholesterol-reducing statins for diabetic patients along with lifestyle change (American 
Diabetes Association, 2018a).   
Cardiovascular comorbidities from type 2 diabetes include myocardial infarction 
(MI), atrial fibrillation, and heart failure, with an increased incidence over time (Larsson 
et al., 2018). It is now an accepted standard of practice in mitigating comorbidity effects 
for physicians to place diabetic patients on a statin. The American Diabetes Association 
recommends a target LDL cholesterol of <100 mg/dl, and the HEDIS CDC measures 
have a quality standard for those with diabetes, assuring they are on a statin medication 
(American Diabetes Association, 2009; National Center for Quality Assurance, 2018c). 
While there are studies that examined the relationship between Medication compliance 
and some of the comorbidities of diabetes, there are none found that have looked at six of 
the classes of diabetes medications, medication compliance with the PDC, and the 
comorbidities of diabetes (Giugliano et al., 2018; Shih et al., 2016). 
Urinary tract infections (UTI) in people with diabetes are generally attributed to 
the kidneys' inability to handle elevated blood sugar values resulting in glucose in the 
urine. Spilled glucose is a food source for bacteria present and can lead to overgrowth 
and infection. In addition to this, people with diabetes may have immune system 
compromises, emptying problems due to neuropathy, and UTI’s in people with diabetes 
are generally more severe, last longer, have worse outcomes, and have more cases of 





 Because diabetes is a complex disease, individuals face self-management 
decisions multiple times daily. Some of these decisions can be complex and are directly 
related to individual outcomes (Brunisholz et al., 2014). Problem-solving is a difficult 
concept to teach and is a daily issue for those with diabetes. Because it is such an 
important part of self-management, the American Association of Diabetes Educators 
hosted a Problem-Solving Symposium that developed 11 key factors in educating people 
with diabetes in dealing with their disease. Several of the key points from that 
symposium include problem-solving is a skill set that can be taught, is impacted by the 
physician’s problem-solving style, it aligns itself with Continuous Quality Improvement 
principles, interventions must address the patient’s highest priority goals, and 
recommendations must be practical (Stetson et al., 2010). 
 Prediabetes is defined as having a blood sugar not high enough to diagnose 
diabetes (Centers for Disease Control and Prevention, 2018a). There are no recognized 
prediabetes symptoms, which presents problems for those who are not visiting a doctor 
regularly. The risk factors for prediabetes include increased BMI, being over 40, having a 
relative with diabetes, participating in physical activity less than three times weekly, ever 
having been diagnosed with gestational diabetes, and being African American, Latino, 
Asian American, or Native American (Centers for Disease Control and Prevention, 
2018b). 
Among the silent complications common to diabetes are retinopathy and 





blindness in the US. Because of its insidiousness, people with diabetes may not recognize 
that they have diabetic retinopathy until it is in its advanced stages (Center for Disease 
Control, n.d.-a).  Thus, the need for annual screenings. Vascular changes in the retina 
characterize diabetic retinopathy. These changes all contribute to the development of 
macular edema from the leaky vasculature of the retina. Of interest is that in people with 
type one diabetes, retinopathy does not usually appear until an individual has diabetes for 
three to five years. However, in twenty-one percent of people with type two diabetes, 
retinopathy has already developed before diagnosis, perhaps due to macular edema and 
capillary nonperfusion (Fong et al., 2004).  
Diabetic nephropathy is defined by increased albumin secretion in the urine. It 
occurs in fifteen to forty percent of people with type one diabetes but less frequently in 
type two diabetics (Gross et al., 2005). Forty-four percent of end-stage renal disease 
comes from patients with diabetic nephropathy. Nephropathy of any origin may also lead 
to an increased chance of stroke (Center for Disease Control, n.d.-b). Smoking may be an 
additional risk factor for diabetes developing nephropathy (Jiang et al., 2017). 
Socioeconomic status and other SDOH are related to participation in retinal and 
renal screenings in diabetics (Fathy et al., 2016; Lee, 2018). Retinal screenings in people 
with diabetes can reduce the incidence of severe vision loss by 94% (Schoenfeld et al., 
2001). However, many recently published diabetic retinopathy studies use old data and 





that needs further research is examining improved medications that could contribute to 
lower retinopathy rates.  
Medication Adherence in Diabetics 
 Of the risk factors that people with diabetes face, medication adherence is the 
easiest way to limit risks. While losing weight, reducing sugar intake, and exercising are 
all techniques that a person with diabetes should use to reduce their risks from diabetes, 
medication adherence should be the easiest and is one of the most significant ways to 
help them keep their A1C levels under control. In newly diagnosed diabetics on 
Metformin with reasonable adherence rates in the first year, HbA1c levels dropped by 
0.75% (Nichols et al., 2016). Proper medication adherence leads to fewer Emergency 
Department visits, better sugar control, fewer hospitalizations, and decreased overall 
medical costs (Capoccia et al., 2015).  
Because of the complications of diabetes, polypharmacy is common. However, the 
need for multiple medications treating co-morbidities leads to lower levels of medication 
adherence. The incidence of low adherence related to medication costs is 16% to 19%, 
with medications costs the second most common factor in non-compliance in people with 
diabetes following depression. (Kang et al., 2018).  Improving health literacy levels and 
numeracy skills are other ways to improve medication compliance in people with 
diabetes (Nandyala et al., 2018). 





Diabetes is a disease of glucose metabolism. There are over 110 million diabetic 
or pre-diabetic individuals in the US (National Institute of Diabetes and Digestive and 
Kidney Diseases, 2017). The complications of diabetes include retinopathy, 
cardiovascular complications, UTIs, and nephropathy, and multiple comorbidities. The 
cost of treatment of diabetes in the US exceeded $80 billion in 2017, or $228 for every 
citizen (American Diabetes Association, 2018b). While there are several proven 
therapeutic modalities available to physicians for the treatment of diabetes, medication 
compliance limits treatment effectiveness (Huang et al., 2018a).  Even with the 
implementation of Medicare Part D covering prescription drug costs, many people with 
diabetes report that they are unable to afford copays and deductibles and are skipping 
doses to compensate (Choi et al., 2017).  
Medication Compliance 
Introduction 
Many people report substantial medication costs, particularly in chronic diseases 
(Kesselheim et al., 2016). A recent Kaiser Foundation study found that one in four US 
senior citizens found it difficult to pay for their prescriptions. Of interest, those 
participating in that study said that prescription drugs made their lives better, but at an 
unreasonable cost. Three in ten of the participants in this study said they are skipping 
their medications because of cost (Kaiser Family Foundation, 2019).  From 2010 to 2015, 





Specialty drugs account for 1% of prescriptions but 30% of spending (Anderson-Cook et 
al., 2019).  
What is Medication Compliance 
There are five broad factors related to medication adherence or compliance, 
including patient factors of medication knowledge and beliefs and the SDOH. Medication 
issues such as how they are packaged, how complex it is to take or administer, cost 
directly affect medication compliance. Factors related to a patient’s physician, such as 
poor communication skills, lack of trust or dissatisfaction, and system-based factors 
related to the patient's lack of follow-up, are pertinent to the compliance discussion. 
Finally, other factors such as caregiver issues, no caregiver, or lack of perceived health 
status improvement also contribute to adherence to medication therapy (Yap et al., 2016).  
An estimated 20% of the population has to deal with medication compliance's 
financial stresses (McHorney & Spain, 2011). When individuals are struggling to pay 
their rent or provide food for themselves or their family, taking their medications takes a 
back seat. They adopt new strategies such as skipping a month, reducing their daily 
dosage such as only taking it once rather than twice a day, or taking a dose every other 
day (Ippolito et al., 2017). These strategies may lead to poorer health outcomes and 
statuses. One MCO has gone so far as to implement a Community Help Line to assist 
individuals with food, rent, transportation, and utility payments because these are serious 





Medication packaging plays a role in compliance. Efforts such as packaging each 
dose individually in bubble packs, packaging all medications together that should be 
taken at a prescribed time, and electronically controlled dispensers connected to 
smartphones are all strategies that are being considered to help improve medication 
adherence. Individual blister packs with medications taken by the time of day are one 
attempt at improving compliance through packaging changes. Risks presented by similar 
products such as pillboxes and pharmacist-provided multi-dose packaging have not been 
thoroughly studied. These other methods do not overcome features such as ease of 
opening the package or bottle and remembering to take the medication.  A recent study of 
different packaging systems found no compliance differences (Gilmartin-Thomas et al., 
2017).  
Poor communication skills on the part of those prescribing medications are 
another issue. This lack of communication by providers is of importance for those with 
low health literacy. Because of their lack of understanding, low health literacy individuals 
are notoriously non-compliant with their medications (Shiyanbola et al., 2018). The use 
of the teach-back method is one way of overcoming compliance issues in patients, 
especially those with low health literacy (Bussell et al., 2017; Dinh et al., 2016). 
Lack of trust or dissatisfaction with providers contributes to low rates of 
medication adherence. A study of individuals with hypertension looked at physician trust 
and medication adherence. The authors found a positive relationship between physician 





study, the authors found that improved trust in providers improved compliance after 
educational programs (Baghikar et al., 2019). Brown et al. (2016) found that trust in the 
health system is another factor in medication adherence. 
System-based factors influence the follow-up of patients on their treatment 
regimen. In Osteoporosis, patients with multiple physicians and physicians with poor 
communication skills contributed to these patients' poor medication compliance (Yeam et 
al., 2018). In a study of diabetics, the authors found that medication benefits and access 
to care (among other factors) are system-based factors related to medication adherence 
(Brown et al., 2016). In a meta-review of medication adherence in diabetes, hypertension, 
and dyslipidemia, the authors found that only 59% of those studied were compliant with 
their medication (Polonsky & Henry, 2016a). Other factors such as caregiver issues, no 
caregiver, or perceived health status improvement contribute to poor medication 
adherence.  
Medication Adherence Importance  
In clinical trials, researchers' assumption that participants are going to adhere to 
their medication regimens may lead to incorrect results. The Vaginal and Oral 
Interventions to Control the Epidemic study had to be halted when the researchers 
discovered that 30% of biologic samples collected had no study medication present 
(Marrazzo et al., 2015). In diabetes, adherence to medications is necessary for keeping 
glucose and HbA1c within normal limits. Comorbidity risk is reduced with controlled 





Adherence and persistence are both critical for people with diabetes to maintain 
glucose control. However, there is conflicting evidence on the contribution of adherence 
and persistence to care costs for diabetics. Chandran et al. (2015) found significant 
overall healthcare costs in insulin pen compliance. Stuart et al. (2015), found that 
although better medication adherence improved glucose control, savings may be offset by 
increased medication costs. Finally, Busyman et al. (2015) found no change in costs 
when looking at adherence and persistence.  
Measurement Tools 
Because medication adherence is an essential topic with health status and cost 
implications, measurement is just as important. There are several tools for measuring 
medication compliance. Among them is the Morisky Medication Adherence Scale, 
Medication Possession Ratio (MPR), Proportion of Days Covered (PDC), and SEAMS. 
These tests have been developed as improvements over previous methods or as tests for 
particular conditions.  
There are three different Morisky scales, the Morisky Medication Adherence 
Scale-4 (MMAS-4, or the Medication Adherence Questionnaire (MAQ)), Morisky 
Medication Adherence Scale-8 (MMAS-8), and the Morisky Green Levine scale 
(MLGS). The MMAS-4 was the first medication-adherence test developed by David 
Morisky and has yes/no answers. While it was the first test of its type, it has a low 
Cronbach’s alpha of 0.61 (Morisky et al., 1986). To create a better tool, Morisky 





and a single Likert scale question. The new test has a Cronbach’s alpha of 0.83 (Morisky 
et al., 2008). The MMAS-8 is a widely used tool for measuring medication compliance 
and is cited in 1985 studies when doing a Google Scholar search. The MLGS test 
comprises four questions with yes/no answers, and the lower the score, the higher 
adherence.  
The MPR tests the relationship between the number of days covered and the 
number of days in the measurement period, first mentioned in the literature in 1993 in a 
study of diltiazem, a calcium channel antagonist (Skaer et al., 1993). In other words, it is 
the days’ medication a person had on hand divided by the number of days being 
measured. An issue with the MPR is that it can exceed 100% when a patient refills the 
medication earlier than needed, and this surplus is counted in the days measured. It is a 
widely used medication adherence measurement tool used to determine adherence in 
comparing different medication delivery systems, hypertension, and medication regimen 
complexity (Ho et al., 2017; Na et al., 2018). However, researchers have some dissension 
on precisely what the MPR is and what it is measuring. In 2017, Sperber, Samarasinghe, 
and Lomax suggested that the MPR should not be used as a static measure of medication 
adherence but should be used only to examine adherence trends. They cited evidence of 
its inability for direct use in studies and to compare values across studies. They suggested 
that using the MRP with upper and lower bounds and not removing patients with limited 





With the MPR, it is possible to have values higher than 100%, and the PDC 
addresses this issue. For example, if two medications are available to an individual for 
180 days during a calendar 365-day period, their PDC value is 0.49.  In this example, an 
individual can possess 480 days of medication for 365 days, and their MPR value would 
be 1.3. A value of 1.3 is neither reasonable nor possible (Patel, 2018).  
The SEAMS test is 13 questions on a 3-point Likert-type scale, medication 
compliance assessment tool. The original was a 21-question survey. This tool has been 
validated for use; however, scoring this tool can be challenging (Lavsa et al., 2011). 
Additionally, the length of time it takes to administer is an issue (Lam & Fresco, 2015).  
SEAMS was developed in 2004 by a group of nurses looking for a medication adherence 
tool that took into account health literacy (Risser et al., 2007). The SEAMS method has 
been widely cited over the last 15 years.  
In 2015, the CDC adopted the PDC measurement as their guide for researchers 
examining medication adherence. The PDC measurement is supported by the Pharmacy 
Quality Alliance and CMS and is the leading method for determining medication 
adherence in large populations (Center for Disease Control, 2015). The PDC is a measure 
of the proportion of doses that should have been taken compared to doses taken while the 
MPR looks at the medications an individual had on hand.  
Self-Assessment and Compliance 
When researchers examine medication adherence based on self-assessment, 





patients and their compliance with retroviral therapy, researchers found a discrepancy 
between participant medication self-assessment and the drug's blood levels (Simoni et al., 
2014).  While the AIDs study found discrepancies, a diabetes study comparing 
medication self-assessment using the Medication Event Monitoring System (MEMS) and 
HbA1c levels, researchers found validity and reliability of the evaluation tool based on 
HbA1c levels suggesting that the type of disease may also be a factor in medication 
compliance (Gonzalez et al., 2013).  Over time, studies have found a significant 
relationship between medication self-assessment and HbA1c levels in people with 
diabetes (Tandon et al., 2015). However, others purport to show that self-assessment 
tools are not valid as they do not correlate well with HbA1c levels (Cohen et al., 2010).    
How Medication Adherence is Measured 
There are two ways to measure medication adherence, direct and indirect 
methods. Direct methods include examining levels of the drug in the bloodstream, 
directly observing dosing, and looking for markers applied to the drug in biological 
samples. Indirect methods include electronic methods counting bottle-opening, pillboxes, 
and self-reporting. These indirect methods are less than ideal because of time 
requirements, cost, or impracticability (McRae-Clark et al., 2015).  
There are issues with the direct methods of measurement. For example, spot blood 
levels only reflect dosage at a point in time, but not longitudinally. Direct oversight, 
while helpful, means that someone must witness every dose taken; if not impossible to 





participants bring in all their medications, which cannot be verified. This method cannot 
determine if the medication was taken as prescribed. For example, a medication is 
ordered three times daily; there is no way to determine if the participant took the 
medication three times daily or all at once in the morning. Researchers only know that all 
the medication was taken by count (McRae-Clark et al., 2015).  
Indirect methods, such as electronic methods that automatically record when a 
medication bottle is opened, may be accurate. However, they are expensive and can be 
impractical (Gonzalez & Schneider, 2011). Pillboxes have the same issue. One can see 
that medication is gone from its compartment, but it is impossible to know for sure that 
the medication was consumed. Self-reporting mechanisms for medication adherence 
depend entirely on the honesty of the one completing the form. It has been found that 
participants in self-assessment tools tend to overstate their compliance. Other methods 
commonly used in assessing compliance are based on pharmacy claims data. However, 
this method has the same potential for error as the others do. Just because a person gets a 
prescription filled, it does not mean that they will take it (McRae-Clark et al., 2015).  
The NCQA has adopted the CDC PDC methodology as its way to determine 
medication compliance. The PDC method suffers from the same problems as other 
compliance methods, but Medicare and Medicaid have adopted it for help in determining 
the financial rewards of those under the HEDIS quality mandates.  





There are several different research tools for determining medication compliance. The 
most common of these is the Morisky Self-Assessment tool. A Google Scholar search of 
Morisky AND MMAS revealed 2340 studies citing this medication compliance 
measuring method since 2016. Ideally, any medication compliance study would be by 
some biological method that measures the quantity of drug in the blood. If measuring the 
drug is not feasible, measuring a metabolic by-product or biological indicator such as 
HbA1c would be ideal. Unfortunately, these are neither practical nor financially viable. 
For now, the best method we have is either the PDC, MMAS-4, or MMAS-8 method. 
Those covered under the HEDIS quality measures are going to have to use the PDC 
measure.  
Health System Quality Overview  
Ernest Codman and Robert Dickinson were early 20th century surgeons who first 
attempted to apply formalized, scientific-based quality to health care. Dr. Codman 
developed an “End Result System” for hospitals to improve surgery centers' low quality 
(Wrege, 1980).  Frank Gilbreth, an efficiency expert, was added to the group to formalize 
their ideas into measurable outcomes. The End Result system was a measuring stick of 
the accepted level of outcomes used to measure patients' surgical outcomes.  
Skipping ahead, in 2001, the Institute of Medicine developed the STEEP model of 
quality (National Institute of Medicine, 2001). This model has been a driving force for 
current models of quality adopted in the US. STEEEP or Safety, Timely care, Effective 





health care quality and are the framework for what is now known as the HEDIS 
measures. One purpose of the HEDIS measures is to help make quality more transparent 
and easier for health care consumers to understand (Agency for Healthcare Research and 
Quality, 2018). However, little attention has been paid to patients in developing these 
standards, nor were patients involved in creating the six domains of health.  
Quality improvement systems currently in use include Plan, Do, Study, Act 
(PDSA), Smart (SMART), Achievable, Relevant, and Time-bound and Continuous 
Quality Improvement (CQI). Edward Deming developed the PDSA methods centered on 
learning from actions taken. Deming worked in Japan during the post-war period and was 
instrumental in improving the quality of Japanese products. PDSA is a rapid cycle model 
where results feedback to actions, leading to study, then improvement. George Doran 
first referenced the SMART system in 1980 (Doran, 1981). The SMART system is a way 
to help clarify goals and ideas and is a way to get to those goals in an efficient and timely 
manner. The CQI process encompasses many different techniques for improving quality. 
The concept behind CQI is that it is a model for reducing or eliminating waste, improving 
efficiency, and is an ongoing process to improve an organization's process.  
NCQA HEDIS quality rating system 
The Healthcare Effectiveness Data and Information Set or HEDIS are the most 
used performance improvement measures in the US. Over 190 million people are 
enrolled in MCO’s and other healthcare systems covered by the HEDIS measure quality 





measures cover six domains of health and 90 different measures. The six domains include 
(National Committee for Quality Assurance, 2018a): 
• Effectiveness of Care. 
• Access/Availability of Care. 
• Experience of Care. 
• Utilization and Risk-Adjusted Utilization. 
• Health Plan Descriptive Information. 
• Measures Collected Using Electronic Clinical Data Systems 
 
A weakness of these measures is that they do not sufficiently account for the 
Social Determinants of Health. There is evidence showing that disparities in health and 
socioeconomic factors contribute to clinical outcomes (Kind et al., 2014). While there 
have been some adjustments in specific measures for Dually Eligible Medicare Members 
(DSNP’s are eligible for Medicare and Medicaid) using the Categorical Adjustment 
Index, there are still not adjusted.  Evidence shows that adjustment of all socioeconomic 
factors measures has value (J. Hu et al., 2018). 
The HEDIS measures are the most widely used quality measurement tools for 
healthcare providers and organizations in the US. They are being used to determine 
financial rewards, which MCO’s get favored treatment in Medicaid state plans, and help 
the public determine which MCO’s they want to belong to. The failure of the NCQA to 
adjust the measures for socioeconomic status continues to present problems for MCO’s. 
Others believe that board adjustments would contribute to reduced quality for the 
disadvantaged. However, evidence disputes this claim.  





One of the HEDIS measures is the CDC measure, which has multiple 
components, including HbA1c levels, eye care, and kidney monitoring. It is defined by:  
1. Hemoglobin A1c (HbA1c) testing. 
2. HbA1c poor control (>9.0%). 
3. Annual Eye exam (retinal) performed. 
4. Annual Renal exam for Nephropathy. 
5. Blood Pressure Control (<140/90 mm Hg, diastolic and systolic values 
must be met to be compliant) 
 
There have been some positive results from implementing this measure in 
Medicare managed care programs. In comparing Medicare 2012 and 2017, retinopathy 
rates improved by 5.1%, nephropathy rates improved 5.6%, the number of patients with a 
completed HbA1c increased by 2.3%, and those with HbA1c levels less than 9% reduced 
by 15.1% (National Committee for Quality Assurance, 2019a).   
Proportion of Days Covered (PDC) 
While the PDC is not a HEDIS measure specifically, it is used to determine 
medication compliance in some HEDIS measures. The first reference to the PDC in the 
literature was 2002 (Benner et al., 2002). Since then, there have been several different 
recommendations for calculating the PDC with the current method, developed by the 
Pharmacy Quality Alliance, having been validated by several sources. The PDC is 
calculated by determining the number of days the medication should have been taken. 
Then the number of doses actually taken by the number that should have been taken.  
For patients on multiple medications, then only count the days when all meds are 





The PDC method is used in determining medication adherence in the HEDIS 
measures and includes these medication classes, Renin-Angiotensin System Antagonists 
(RASA), all classes of diabetes drugs, some psychotropics, and statins. The HEDIS 
measures use the CDC version of the PDC in determining how well healthcare 
organizations are doing at monitoring their members' medication adherence and should 
be used in interventions for improving compliance. The Medicare CDC measure is 
calculated based on all medications taken during the measurement year.  For the studies 




The HEDIS metrics are the current step in the development of healthcare quality. 
They cover 90 different aspects of healthcare quality and are used by Medicare, 
Medicaid, and Commercial payers in determining quality ratings, bonus or penalty 
payments, and are promoted to the public as a tool to help them determine which MA 
plan they want to join. The NCQA reviews every health care provider under the HEDIS 
measurements annually. The NCQA collects HEDIS results, and a substantial set of 
information for researchers and others is in this data store. The NCQA uses this data in 
identifying aspects of health that might lend themselves to quality measures. A National 
Institutes of Medicine workshop examined if it is time to create health literacy measures 





of Sciences Engineering Medicine, 2018). The jury is still out on the results of this 
workgroup. 
Star and HPR rating systems 
Medicare Star Score Rating System 
CMS uses the Medicare Star Score system to rate the performance of and 
determine bonus payments for Medicare Advantage (MA) plans and other health care 
providers. The rating system incorporates different quality measures taken from different 
surveys done during the year. The surveys are the HEDIS measure, the Health Outcomes 
Survey (HOS), and the Consumer Assessment of Healthcare Providers and Systems 
(CAHPS). Each of these surveys measures different areas of compliance. Medicare 
requires that all MCO’s submit these surveys on an annual basis. The Star Score rating 
scale ranges from one to five in whole number increments. 
The HEDIS quality measures look at the clinical aspects of care, including 
clinical outcomes, participation in preventive screenings, and medication adherence. 
Outcome evaluations in the HEDIS quality measures include diabetes measures that look 
at how well blood glucose levels are controlled, whether statins are appropriately 
prescribed, rates of depression, and how compliant individuals are with their medications. 
The measures are updated annually, with changes announced in the release of a set of 
technical notes. These notes identify precisely how each measure is calculated and what 





or retired from active status. Body Mass Index measurement is an example of this and is 
being retired in the calendar year 2020. 
Star Score Financial Awards and Penalties 
Medicare wants to link MCO payments with quality. The 2012 Affordable Care 
Act (ACA) included provisions that tied MCO payments to quality measures (Patient 
Protection and Affordable Care Act, 2010). There are billions of dollars available to 
MCO’s for improving their quality in both insurance and prescription drug plans. 
Between 2012 and 2014, CMS paid out $10.9 billion in quality bonus payments (L&M 
Policy Research, 2016).  
The star ranking system provides penalties for MCO’s that do not reach a 3-star 
rating. Payment penalties are in the form of lost bonuses and rebate payments. If a plan is 
rated at one star, there is a loss of 9% of the contracted payment rate. For two stars, there 
is a loss of 4.5% of contracted payment amounts. A three-star rating is neutral, and four-
star programs receive a 4.5% bonus, and 5-star programs receive a 5% bonus in addition 
to rebates. Four and 5-star programs get an additional benefit in that they can enroll 
members at times other than the Medicare Annual Election Period. However, MCO’s 
cannot keep all of the bonus payments. Some of it must be returned to its members in 
improved benefits (Elisver, n.d.). Having extra money to improve benefits makes higher-
quality plans more attractive to the public.  





The Medicaid Health Plan Rating system (HPR) is based on HEDIS results, 
CAHPS, and NCQA Accreditation standards scores (National Committee for Quality 
Assurance, 2019c). The purpose of this rating system is to help states better choose the 
MCO they contract with. The HPR rating scale ranges from one to five. The HPR system 
follows the NCQA quality rankings ranging from 0 to 5, but unlike the Medicare Star 
ranking system, the HPR system is ranked in 0.5 intervals.  
A plan’s overall NCQA rankings are determined by a complicated set of rules 
based on having a set amount of data to analyze, length of time the organization has been 
established. Additionally, measures can be weighted from one to three, where process 
measures have a value of one, and clinical measures are weighted at three. (National 
Committee for Quality Assurance, 2018b). Any plan that submits HEDIS and CAHPS 
surveys is eligible for ranking.  
Health Plan Rating Financial Awards and Penalties 
State Medicaid programs reward MCO’s in several ways. There is withhold 
money that is returned at the end of the year. New members may be auto-assigned based 
on a plan based on HPR ratings, with more members going to better plans, and finally, 
liquidated damages. Medicaid Plans participating in a capitated payment program receive 
withholds from payments until quality rankings are determined at the end of each year. 
Plans receive back an amount of their withhold money based on their quality scores. 





such as pharmacy or dental benefits, and handle them within the state system rather than 
the MCO.  
Those who qualify for Medicaid are given a chance to choose the plan they want 
to join. However, if they fail to do so, they are auto-assigned to a plan. Auto-assign is a 
methodology that state Medicaid plans use to determine which participants are assigned 
to which plans. These auto-assignment methodologies do vary from state to state (Smith 
et al., 2015). Since 2015, 19 state Medicaid MCO’s contracts include quality 
requirements and have withhold systems included in their contracts (Smith et al., 2019). 
These withhold programs can include substantial amounts of money, reaching the $10’s 
of millions in some states.  
Medicare Low Income Subsidy (LIS) and Dually Eligible Special Needs (DSNP) 
Programs 
 Individuals with a monthly income of less than $1650 for individuals and $2,175 
for couples and limited assets are eligible for a Medicare Part D subsidy known as the 
LIS program administered by Medicare under the Extra Help program. The program 
helps pay for prescription costs, premiums, deductibles, and coinsurance $8.95 (Centers 
for Medicare & Medicaid Services, n.d.). The program was established under the 
Medicare Modernization Act, with 4.7 million enrolled in the LIS program in 2018 
(Centers for Medicare & Medicaid Services, 2020a). LIS programs are only available for 
those enrolled in a Medicare Advantage and Prescription Drug plans or Prescription Drug 





Hole in Part D Medication coverage. The Donut Hole is a range of costs for medications 
that are not covered by MA plans, generally between $3,000 and $4,500, where members 
pay all of their prescription costs. The program's purpose is to take advantage of the 
associated lower medical costs related to improved compliance (Kirkman et al., 2015).   
 While the LIS program attempts to address some health problems around income 
inequality, it has some problems. The LIS program offers lower copays and premiums, 
but the deductibles may be higher than before being on the LIS program, and the MA 
formularies limit some medications.  Both copays and deductibles are related to health 
inequalities and medication adherence.  One of the studies presented looks at how the LIS 
program and medication compliance for individual antihyperglycemic medications 
control HbA1c levels.  
 DSNP programs are designed for those below the poverty level and include those 
in Medicare Part A and Part B and getting full Medicaid benefits, including Medicare 
premium assistance. In the DSNP program, Medicare is the primary payor, and Medicaid 
is the secondary payor. Medicaid also covers items and services not covered by Medicare 
but covered by the state Medicaid program. States control the income limits, but it is 
generally a requirement that the enrollee’s income is below the poverty level, currently 
set between $12,760 and $44,120, depending on the number of individuals in the 
household (U.S. Department of Health and Human Services, 2020). There are also asset 
limitations for enrollment in the DSNP program. There are eight different participation 





 For the studies presented here, DSNP and LIS participation are used to measure 
income and education levels or Social Determinants' indicators. A 2018 Health and 
Human Services documented the relationship between DSNP enrollment and Social 
Determinants issues (Sorbero et al., 2018). DSNP enrollees have an income at or below 
the poverty level. LIS enrollees cannot be over 300% of the poverty level. Finally, we 
have the other participants of this study who are not in either of these programs and will 
be assumed to be not eligible for either of these programs. Therefore, we have a 
categorical variable of income with non-participation at the highest level of income, LIS 
at the middle level of income, 300% to 100% of the poverty level, and DSNP enrollees 
the lower level of income either at or below the poverty level. Having actual income 
levels would be a better approach, but the MCO does not collect that information, so we 
use the data available in the best way we can.   
Other Considerations in Analysis 
The data used in these studies came from a large MCO and were analyzed as 
secondary data.  The individual variables used across these studies are: 
Table 1  
Predictor Variables, their type, and possible values 
 
Variable Name Variable Type Possible Values 
Unique member identifier. Nominal Format TBD by MCO 
Age Continuous 21-100 
Sex Categorical 0=male,1=female 
HBA1c level  Continuous actual level 
Regional area of US  Categorical  N, E, S, W 
Deductible Continuous actual level 
Medication Class Ordinal 1-35 





Mean Adjusted Medication PDC Continuous 0-1 
Had Retinopathy Screening Nominal 0=no, 1=yes. 
Had Nephropathy Screening Nominal 0=no, 1=yes. 
Diabetes diagnosis time Ordinal In days 
Length of time in the plan Ordinal In days 
Plan type  Categorical 1=PDP, 2=MA + PDP 
Seeing an Endocrinologist Nominal 0=no, 1=yes. 
Had Myocardial Infraction  Nominal 0=no, 1=yes. 
Is Blind  Nominal 0=no, 1=yes. 
Has End-Stage Renal Disease Nominal 0=no, 1=yes. 
Had Urinary Tract infections Nominal 0=no, 1=yes. 
LIS enrollment   Categorical 0=no, 1=yes 
Dual enrollment Categorical 0=no, 1=yes 
 
The generally accepted demarcation between an Urban and Rural area is a 
population of more than 50,000. However, in 1910, the Census Bureau modified that 
definition to include Urban Clusters as an area where the population threshold is between 
2,500 and 50,000. For example, a small city located in a rural part of the country with 
3,000 is considered an Urban Cluster. Those living outside of the city limits would be 
considered living in a rural area (U.S. Census Department, n.d.).  
There are nine diabetes medication classes used in treating type 2 diabetes based 
on their mechanism of action (Feingold, 2019). Injectable medications are not included 
because the PDC methodology cannot be used for injectables.  For this study, we are only 
looking at six of the nine classes included in the MCO formulary which include 
Biguanides, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Thiazolidinediones, 
Sulfonylureas, Meglitinide Analogues, Sodium-Glucose Co-Transporter 2 (SGLT2) 
Inhibitors. Additionally, the six classes of commercially available combinations of 





These six combination classes are Meglitinide-Biguanide, SGLT2 Inhibitor - DPP-4 
Inhibitor, Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide, Sulfonylurea-
Biguanide, Dipeptidyl Peptidase-4 Inhibitor-Biguanide, Sulfonylurea-Thiazolidinedione.  
The final issue to address in these dissertation studies is what four comorbidities 
to use in the analysis. The EQ-5D score is a questionnaire that scores chronic conditions 
in the United States and the United Kingdom with data taken from the Medical 
Expenditure Panel Survey. This questionnaire is used for both cost-effectiveness studies 
and public health modeling. Myocardial Infarction, Blindness, End-Stage Renal Disease, 
and Urinary Tract Infections (UTI) are the four diabetes comorbidities that will be used in 
these studies, and the following ICD-10 diagnosis codes for type 2 diabetes are being 
used E11.40, E11.51, E11.29, E11.36, E11.21, E11.319, E11.65, E11.311, E11.39, E11.9 
(Sullivan & Ghushchyan, 2016).  
Predictive Analytics  
Predictive Analytics is the use of statistics, data, and in some cases, machine 
intelligence to predict future outcomes. Even though predictive analytics is a hot topic in 
many fields, the concept has been around since the late 1700’s when Lloyds of London 
used predictive analytics in determining risks around insuring goods or assets. We live in 
a world of predictive analytics that includes foretelling our future purchase activities, 
what we want to watch on TV, and how marketing efforts can influence voting (Bradlow 





has grown in importance, particularly in predicting clinical and intervention outcomes 
(Harris et al., 2016; Lin et al., 2017).  
Healthcare big data and Electronic Health Records (EHR) are two areas where 
predictive analytics are used extensively within healthcare. Big Data is defined as 
voluminous and complex data beyond the ability of traditional data analytic systems. The 
term is evolving to include predictive analytics or behavior analysis (Ongsulee et al., 
2018).  Healthcare systems collect massive amounts of data on their members. MCO’s 
have extensive claims data on their members, and government data sources are even more 
significant. All these transactional data can be applied to predictive analytics to help 
improve outcomes and health statuses.  
Predictive analytics foretells outcomes and future needs for people with diabetes. 
One study looking at readmission of people with diabetes used predictor variables such as 
labs, number of medications, admission time, number of inpatient visits and found that 
they are all predictive of future hospital admissions (Srinivasan, 2018).  Having this kind 
of data gives MCO’s tools for reducing future diabetic readmissions and reducing costs. 
In an international study of flu vaccination rates in people with diabetes, predictive 
analytics showed that it is necessary to account for country-specific behaviors when 
creating flu vaccination interventions for people with diabetes (Liska et al., 2018).   
Predictive analytics have been used to find future diabetics. It was found that 
oversampling and the use of 16 predictors worked well in predicting both short and long-





While predictive analytics is mainstream in healthcare, caution must be exercised 
in conclusions. With many free software applications for predictive analytics available, 
analysis is as easy as downloading the application, plugging in the data, and looking at 
the results. However, potential harm from these analytics is there and must be considered. 
Determining clinical procedures based on analytics can be problematic at an individual 
level.  “The potential of prediction to influence decision making also implies the potential 
for harm, through the dissemination of misinformation at the point of care. This potential 
for harm from insufficiently validated models in a profit-driven market suggests the need 
for oversight (Kent et al., 2018, p. 2).”  
Studies one and two examine the association between HbA1c levels OAMC and 
PDC and not whether HbA1c is controlled to PDC levels, and how financial assistance 
programs impact PDC and HbA1c levels. For these studies using HbA1c as a continuous 
variable is appropriate because the continuous variable gives much better granularity.  
Also, for these two studies, examining HbA1c as a categorical variable would give too 
large of variation in values and what would be meaningful value ranges?  Finally, 
determining proper and clinical appropriate ranges for a categorical HbA1c would be 
difficult.   
 
Variance Inflation Factors (VIF) 
VIF is a statistical analysis that looks for collinearity. Collinearity is an effect 





effect. Collinearity may cause increased variance in predictors, produce models where a 
sizeable R2 value is present even though no predictors are statistically significant, 
confuses the direction of effect, and produce a model where small predictor changes 
produce significant variances in the outcome (O'Brien, 2007).  
A generally accepted value for VIF that expresses collinearity or multicollinearity 
is 10. However, using this rule of thumb must include cautions. As related to these 
studies, we must use caution in interpreting the VIF. One factor to consider is that some 
of the medication classes are a combination of the single medication classes, which could 
induce collinearity. Another factor to consider is that even if the regression predictors 
show collinearity, we will only use one of the medication class predictors at a time.  For 
example, our regressions are designed for use when an individual is on one medication, 
and we are attempting to predict their HbA1c level when they are changed to another 
medication. In using the equation, all the other medications classes are removed from the 
prediction because their value in the equation is 0, eliminating the potential for 
interaction between medications.  
Summary 
 Diabetes is one of the fastest-growing chronic diseases health care providers face, 
and the comorbidities of diabetes are numerous and severe. Most of the blindness in the 
country is related to diabetes, as is end-stage renal disease. Both impact individuals’ 





 Medication adherence is a serious issue. Medical treatments have their foundation 
in the use of medications. When prescribed and medications are not taken as directed, not 
only do individuals face failed treatment plans, but physicians are generally not aware 
that their patients are non-compliant and may misdiagnose problems. Determining 
adherence is a tricky proposition as people tend not to be honest when completing 
medication compliance surveys, furthering the difficulty of assessing adherence. The best 
currently available tool for measuring medication adherence is the PDC.  
 While the current literature discusses medication compliance in people with type 
2 diabetes, there are no studies to date that examine the relationship between the classes 
of medications, compliance with those medications, and HbA1c levels. Additionally, no 
studies have looked at this same relationship and the comorbidities of type 2 diabetes. 
Finally, Medicare created financial supplement programs that lower deductibles and 
copays. There are no studies to date examining the effectiveness of these programs in 
lowering HbA1c levels. These are the gaps that these studies look to close.  
 MCO’s face financial penalties for not attaining set quality goals for diabetes and 
medication adherence. Additionally, Medicaid MCO’s face populations with lower health 
literacy levels, high rates of chronic conditions, and lower health statuses. Putting all this 
together, we have the toxic mix of chronic diseases that are not understood by those that 
have them, in part, due to low health literacy. We have diseases that require medication 
adherence for successful treatment, people who tend to be non-compliant, and insurers 





people. The study's purpose is to provide tools for healthcare organizations to identify 
those at risk for higher HbA1c levels and at risk for the comorbidities of diabetes.  
Overview of the Manuscripts 
Manuscript 1 short description 
This manuscript's title is “Medication Compliance by Drug Class as a Predictor of 
HbA1c Values in Medicare Type 2 Diabetics.”  Participants have type 2 diabetes and 
were enrolled in a Medicare Advantage plan in 2018. The PDC is the medication 
adherence methodology Medicare and Medicaid MCO use in measuring medication 
compliance in members. The PDC is a ratio of the number of doses of a medication that 
should have been taken over a measurement period of at least six months and calculated 
from claims data readily available to MCO’s (Centers for Medicare & Medicaid Services, 
2015). In diabetics, longer-term glucose values are measured by the HbA1c test. The 
advantage of using the HbA1c level is that it correlates with the glucose levels over the 
last several months. HbA1c has been the accepted method for monitoring glucose levels 
since 2011 (Malkani & Mordes, 2011). This study's medications are six of the nine 
classes of medications used in treating type 2 diabetes (Feingold, 2019). This study 
provides a predictive tool to assist MCO in identifying members at risk for future 
uncontrolled HbA1c levels based on their PDC.  Linear regression analysis is appropriate 
here because the outcome variable in this study, HbA1c level, is a continuous variable 





Studies show an association between PDC and HbA1c levels (Nichols et al., 
2016). One study showed that HbA1c levels are reduced by 0.6% in newly diagnosed 
diabetics with a PDC greater than 80%, and in those with a PDC less than 80%, the 
reduction was only 0.4% (Nichols et al., 2016).   While other research has looked at 
individual medication compliance using the PDC, none have made a comparison of the 
six antihyperglycemic class medications and HbA1c and attempted to develop predictive 
modeling around these classes of medications.  Statistical analysis was used to determine 
whether individual antihyperglycemic medication classes and the PDC can be used to 
predict future HbA1c levels. Other medication compliance measures, MPR, and the 
Morisky scores, have been used and have shown that medication compliance in diabetics 
leads to lower levels of HbA1c (Capoccia et al., 2015). This study uses the PDC, the 
current CMS, and CDC-recommended medication compliance method (Centers for 
Medicare & Medicaid Services, 2015).  
Manuscript 2 short description 
Manuscript two examines the relationship between participation in Medicare LIS 
and DSNP financial assistance programs and the PDC for the six classes of 
antihyperglycemic medications on HbA1c levels. We only chose those who had taken 
just one of the classes of antihyperglycemic medication classes during the year because 
we are not able to relate HbA1c levels to a single medication if they took more than one 
during the year. Medicare sets maximun income and asset levels for participation in these 





compliance and thereby reduce HbA1c levels. Study participants are in one of three 
categories, those not in a subsidy program, those in a LIS program, and those in a DSNP 
program. Linear regressions analyze the data to determine the effectiveness of these 
programs in improving PDC rates and lowering HbA1c. As of this writing, there are no 
peer-reviewed studies found that examine the effect of Medicare subsidy programs on 
HbA1c levels in MA type 2 individuals with diabetics using the PDC methodology and 
antihyperglycemic medication classes. The title for this manuscript is "Dually Eligible, 
Low-Income Subsidy Enrollment, and Medication Compliance as Predictors of HbA1c in 
Type 2 Diabetics." 
Manuscript 3 short description 
In manuscript three, we are analyzing medication compliance in the six classes of 
antihyperglycemic medications, HbA1c levels, and examining whether they can be used 
to predict four of the comorbidities, or combinations of comorbidities, of type 2 diabetes. 
Diabetes is a chronic disease that produces a number of comorbidities so being able to 
relate compliance with oral antihyperglycemic medciations or HbA1c to chances of 
developing a comorbidity would be helpful to practitioners (Luo et al., 2017).  To date, 
there have been no peer-reviewed studies found looking at this topic. This study has 
significance to the medical community in that it may find that certain classes, along with 
the compliance of those medications, may do a better job at reducing the incidence of 
comorbidities. We are only selecting participants taking one class of antihyperglycemic 





our outcome variables, comorbidity, or sets of comorbidities, are binary. This 
manuscript's title is "Medication Compliance, HbA1c Predicting Comorbidities in 
Medicare Type 2 Diabetics." 
Significance 
There are implications that can have tens of millions of dollars in penalties 
associated with failure to meet Medicare quality goals. Of even more significance are the 
medical costs associated with patients or members who do not comply with the HEDIS 
standards of care.  Third, there are the societal penalties of poorer health statuses 
associated with individuals who are non-compliant with HEDIS diabetes measures.  
These studies look at topics of clinical significance for the treatment of MCO 
individuals with type 2 diabetes. There is a well-documented relationship between 
individual medication compliance and HbA1c using the PDC. The first study looks to see 
if there is a relationship between medication compliance and the different 
antihyperglycemic medication classes and individual HbA1c levels. We examine 
medication classes combined with compliance rates based on the PDC and determine if 
this is an effective way of determining new medications when attempting to lower 
HbA1c levels. We look to answer whether one medication with a lower compliance rate 
more effectively reduces HbA1c levels than another medication with a higher compliance 
rate. This study could be of significance given the medication compliance issues present 





The second study looks at Medicare financial subsidy programs and the 
relationship between these and HbA1c levels, which has little discussion in the literature.  
One purpose of these programs is to help individuals make their copays and deductibles 
for their prescription medications. In those with type 2 diabetes, this assistance has an 
aim at improving medication compliance. In people with diabetes, medication 
compliance equals better HbA1c control. This study looks to validate that premise.  
Study three will examine the relationship between medication compliance, HbA1c 
levels, and the incidence of four of the common comorbidities of diabetes, Blindness, 
Urinary Tract Infections, Myocardial Infarctions, and End-Stage Renal disease.  This 
study's significance is to see if the combined relationship between HbA1c levels, 
medication class, and compliance has different comorbid complications rates. Suppose 
we find that even though there is a lower compliance rate for a class of medications, there 
is a lower rate of comorbidities. In that case, this is a clinically significant finding for 
future medication therapies showing that not only is a particular medication choice 
important but that medication compliance should also be part of the clinical decision 
process.  
Summary 
The HEDIS CDC measure has four subcategories: HbA1c under control (< 8%), 
completing an HbA1c during the calendar year, controlled blood pressure (under 140/90), 
and were there renal and retinal screening performed in the calendar year. MCO’s face 





However, controlling blood sugar and HbA1c levels is entirely up to individual 
healthcare organization members.  
Medicare and Medicaid adopted the HEDIS quality measures to determine the 
financial rewards for healthcare organizations. These rewards can be significant, and 
MCO’s struggle to get their members compliant with quality measures. The studies 
presented establish relationships between medication compliance, oral antihyperglycemic 
medication class, financial programs, and diabetes comorbidities. MCO’s can use this 
evidence to helps improve individual health statuses and assist organizations earn or 
recoup financial rewards to meet the HEDIS CDC measure requirements.  
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Medication therapy is a crucial component in managing diabetes, yet compliance rates 
only approach 50% after the first year of diagnosis. Managed Care Organizations (MCO) 
face considerable financial stress with rewards and penalties reaching millions of dollars 
for achieving set standards of care, including several diabetes measures. The Centers for 
Disease Control (CDC) accepts the Proportion of Days Covered (PDC) as the current 
research method for establishing medication compliance. The association between 
medication compliance using the PDC and oral antihyperglycemic medication (OAMC) 
and HbA1c levels has not been studied. This study aimed to determine the association 
between medication compliance, as determined by the PDC, and six of the OAMCs. This 
is the first study establishing the association between medication compliance, measured 
by the PDC, and one of six OAMC and by not specific medications.  Sample selection 
included those over 21 years of age, took only one of six OAMCs, having an HbA1c 
level completed, diagnosed with type 2 diabetes selected from the 2019 claims database 
of a large MCO yielded 23,000 participants. Multiple regression analysis shows that as 
PDC rates improve, Sulfonylurea Biguanides have 27 times more impact on HbA1c 
control, and the DPP-Biguanide and Thiazolidinediones classes are ten times more 
effective when compared to the Dipeptidyl Peptidase-4 (DPP-4) medication class. These 
findings may help providers promote positive social change by establishing the 
importance of considering patient compliance when making medication selection in 







U.S. individual medication non-adherence costs for people with type 2 diabetes 
are approximately $28,824 per year (Kennedy-Martin et al., 2017). There are several 
methods for measuring medication compliance, but the most commonly used are the 
Medication Possession Ratio (MPR) and the Proportion of Days Covered (PDC) (Cutler 
et al., 2018). Both use algorithms that consider the proportion of prescribed medication 
doses that should have been taken to the number taken. (Center for Disease Control, 
2015).  The Pharmacy Quality Alliance (PQA) created the current version of the PDC, 
and the CDC has since endorsed it as acceptable for research purposes (Nau, 2012). 
The use of dispensing data has been validated by the PQA and has been used in 
the literature for the last twenty years (Martin et al., 2009). Having compliance 
methodologies utilizing dispensing data, such as MPR or PDC, that can be extracted from 
MCO claims data to measure compliance provides convenience and usability when 
resources are limited.  The first of these is the MPR. The MPR medication adherence 
measurement tool is used to determine compliance in comparing different medication 
delivery systems, hypertension, and medication regimen complexity (Ho et al., 2017; Na 
et al., 2018). An issue with the MPR is that it may overstate compliance due to its 
methodology. The PDC evolved from an effort to improve this weakness in the MPR and 
in 2015, the CDC adopted the PDC measurement as their accepted methodology for 
researchers examining medication compliance. The PDC’s advantage over other methods 





measurement period and not, as with the MPR, what they possessed. The PDC 
measurement is now the leading method for determining medication adherence in large 
populations (Center for Disease Control, 2015).   
The National Committee for Quality Assurance (NCAQ) developed Healthcare 
Effectiveness Data and Information Set (HEDIS), a set of quality measures affecting 190 
million Americans, and is used by Medicare and State Medicaid programs in their quality 
initiatives (National Committee for Quality Assurance, 2018a). Several of the HEDIS 
quality measures use the PDC to measure medication compliance: D10 
Medication Adherence for Diabetes Medications, D11 Medication Adherence for 
Hypertension (RAS antagonists), D12 Medication Adherence for Cholesterol (Statins), 
D14 Statin Use in Persons with Diabetes (SUPD) (Center for Disease Control, 2019). 
Medicare set PDC level greater than 80% as an acceptable rate of compliance. Regression 
analysis were performed on a mean adjusted PDC index for each of six classes, or the 
combination of any of six classes of diabetes medications, Biguanides, Dipeptidyl 
Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, Thiazolidinediones, Meglitinide 
Analogues, and Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (these are the 
classes with enough participants).  
There are numerous studies in the literature establishing relationships between 
medication adherence and HbA1c levels. One study used a modified PDC called the 
Biologic Response Based Proportion of Days Covered (BRB-PDC) and found that 





is related to lower HbA1c levels (Nichols et al., 2016).  A 2016 meta-study found a 
relationship between medication adherence in diabetics and HbA1c levels (Capoccia et 
al., 2016).  Other studies have established the association between the PDC measurement 
and HbA1c levels (Polonsky & Henry, 2016; Ramos et al., 2018). However, no studies to 
date have established the relationships between the PDC and antihyperglycemic 
medication class. The purpose of this study is to determine what association exists 
between the PDC and the individual classes of antihyperglycemic medications and 
HbA1c levels.   
Research Design and Methods 
Creswell (2017) said that a quantitative approach is appropriate when a researcher 
tries to establish relationships between dependent and independent variables. This is a 
longitudinal retrospective study looking at 2019 MCO secondary data. Since the purpose 
of this study is to determine the quantitative relationship between the PDC for the six 
different classes of antihyperglycemic medications, individually and in combination 
(independent variables), and HbA1c levels (dependent variable), the quantitative 
approach is appropriate.  
Research Questions: 
RQ1:   What is the relationship between the PDC and the antihyperglycemic class of 
medication on HbA1c in Medicare type 2 diabetics while controlling for age, sex, 





retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood pressure?  
H01: There is no statistically significant relationship between the PDC and the 
Biguanides class of medications on HbA1c in Medicare type 2 diabetics while 
controlling for age, sex, deductible, number of hospital visits, seeing an 
endocrinologist, participation in renal and retinal screenings, having a diagnosis 
of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure?  
H11: There is a statistically significant relationship between the PDC and the 
Biguanides class of medications and HbA1c values in Medicare type 2 diabetics 
while controlling for age, sex, deductible, number of hospital visits, seeing an 
endocrinologist, participation in renal and retinal screenings, having a diagnosis 
of blindness, myocardial infarction, UTI, or end stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure.  
H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-






H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure.  
H12: There is a statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure.  
H02: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications and HbA1c values 
in Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-






H03: There is no statistically significant relationship between the PDC and the 
Thiazolidinedione class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H13: There is a statistically significant relationship between the PDC and the 
Thiazolidinedione class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure.  
H04: There is no statistically significant relationship between the PDC and the 
Sulfonylureas class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H14: There is a statistically significant relationship between the PDC and the 
Sulfonylureas class of medications and HbA1c values in Medicare type 2 





seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure.  
H05: There is no statistically significant relationship between the PDC and the 
Meglitinide Analogues class of medications and HbA1c values in Medicare type 2 
diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H15: There is a statistically significant relationship between the PDC and the 
individual Meglitinide Analogues class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure.  
H06: There is no statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 





infarction, UTI, or end stage renal disease, LIS enrollment, DSNP enrollment, and 
controlled blood pressure. 
H16: There is a statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, 
and controlled blood pressure. 
RQ2:   What is the relationship between PDC and combinations of antihyperglycemic 
classes of medications and HbA1c values in Medicare type 2 diabetics while controlling 
for age, sex, deductible, number of hospital visits, seeing an endocrinologist, participation 
in renal and retinal screenings, having a diagnosis of blindness, myocardial infarction, 
UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure? 
H07: There is no statistically significant relationship between the PDC and the 
Meglitinide-Biguanide Combinations class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 





stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure.  
H17: There is a statistically significant relationship between the PDC and the 
Meglitinide-Biguanide Combinations class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H08: There is no statistically significant relationship between the PDC and the 
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, 
and controlled blood pressure.  
H18: There is a statistically significant relationship between the PDC and the 
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 





infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, 
and controlled blood pressure.  
H09: There is no statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, 
and controlled blood pressure. 
H19: There is a statistically significant relationship between the PDC and the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications and 
HbA1c values in Medicare type 2 diabetics while controlling for age, sex, 
deductible, number of hospital visits, seeing an endocrinologist, participation in 
renal and retinal screenings, having a diagnosis of blindness, myocardial 
infarction, UTI, or end-stage renal disease, LIS enrollment, DSNP enrollment, 
and controlled blood pressure. 
H010: There is no statistically significant relationship between the PDC and the 
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type 
2 diabetics while controlling for age, sex, deductible, number of hospital visits, 





diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H110: There is a statistically significant relationship between the PDC and the 
Sulfonylurea-Biguanide class of medications and HbA1c values in Medicare type 
2 diabetics while controlling for age, sex, deductible, number of hospital visits, 
seeing an endocrinologist, participation in renal and retinal screenings, having a 
diagnosis of blindness, myocardial infarction, UTI, or end-stage renal disease, LIS 
enrollment, DSNP enrollment, and controlled blood pressure. 
H011: There is no statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c 
values in Medicare type 2 diabetics while controlling for age, sex, deductible, 
number of hospital visits, seeing an endocrinologist, participation in renal and 
retinal screenings, having a diagnosis of blindness, myocardial infarction, UTI, or 
end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H111: There is a statistically significant relationship between the PDC and the 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications and HbA1c 
values in Medicare type 2 diabetics while controlling for age, sex, deductible, 
number of hospital visits, seeing an endocrinologist, participation in renal and 





end-stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H012: There is no statistically significant relationship between the PDC and the 
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
H112: There is a statistically significant relationship between the PDC and the 
Sulfonylurea-Thiazolidinedione class of medications and HbA1c values in 
Medicare type 2 diabetics while controlling for age, sex, deductible, number of 
hospital visits, seeing an endocrinologist, participation in renal and retinal 
screenings, having a diagnosis of blindness, myocardial infarction, UTI, or end-
stage renal disease, LIS enrollment, DSNP enrollment, and controlled blood 
pressure. 
Population and Study Sample 
In longitudinal studies, participants are followed over long periods. Retrospective 
study designs look at past events related to the subject of study (Caruana et al., 2015). 
Longitudinal retrospective studies last over time while examining selected events at 





relationship between various predictor variables and HbA1c levels. Participants were 
selected based on enrollment in an MCO, having a type 2 diabetes diagnosis, over 21 
years of age, taking only one class or combination class of antihyperglycemic 
medications during the past 2019 year. 
To calculate the minimum sample size needed for each of the research questions 
G*Power, version 3.1.9.4, was used with an effect size of 0.15, an alpha error probability 
of 0.05, a power of 0.95, to yield a recommended sample size of 89. The effect size was 
determined based on findings from a meta-analysis of medication compliance studies 
with different diseases, which found that studies with more than 85 participants and effect 
sizes of 0.17 to 0.18 had high statistical power with P < 0.0001 (Foot et al., 2016).  G* 
Power's effect size is a method to quantify the differences between the test and control 
groups and is based on Cohen’s effect size or the explained variance and error variance 
(Cunningham & McCrum-Gardner, 2007). We chose a small effect size, which means the 
difference between the two variances is not important, because  the large sample size of 
56,000  provides more than sufficient participants to achieve statistical power (Cohen, 
2013).  
Our sample includes individuals enrolled in a Medicare Advantage plan (MA) 
with a type 2 diabetes diagnosis based on 2019 claims data. Participants are over twenty-
one and took only one of the six classes or a combination of antihyperglycemic 
medications during 2019. Those who took more than one of the antihyperglycemic 





according to the ICD-10 World Health Organization International Statistical 
Classification of Diseases and Related Health Problems. Cases were selected using the 
ICD-10 diabetes diagnosis code of E11.9, claim data from pharmacy dispensing records 
at outpatient pharmacies. The PDC measurement does not include those on insulin, so we 
did not include members on insulin. MCO members were included in the study until 
disenrollment, death, or the end of the study period. All the data provided by the MCO 
was deidentified with a unique serial number that is with the released data. 
We divided the sample group into two groups using a data-splitting technique 
consisting of a learning group and a holdout group (Picard & Berk, 1990). We split our 
samples into our learning group and holdout group, 70% into the learning used for 
analysis, and 30% holdout used to test our analysis, based on Pang, H., & Jung, S. (2013). 
We conducted our data analysis using SPSS version 27 using the standard p-value of < 
0.05 to indicate statistical significance. Multiple linear regression analysis was used to 
determine the effect each of the predictors has on the outcome variable, the continuous 
HbA1c value, and determining which of the predictor variables has a statistically 
significant effect on the outcome (Warner, 2013).  
The American Diabetic Association established that any HbA1c value higher than 
6.5% is considered diagnostic for diabetes (American Diabetes Association, 2018c). 
Categorical variables were dummy coded for inclusion in these analyses. There are four 





comorbidities, third, the PDC alone, and fourth, all of the items in Table 2 to determine 
the regression equations for each of our research questions.  
Table 2  
 
Predictor Variables, their type, and possible values 
 
Variable Name Variable Type Possible Values 
Unique member identifier. Nominal Format TBD by 
MCO 
Age Continuous 21-103 
Sex Categorical 0=male, 
1=female 
HBA1c level  Continuous actual level 
Regional area of US  Categorical  N, E, S, W 
Medication Class Categorical 1-35 
Medication PDC (mean adj) Continuous 0-1 
Diabetes diagnosis time Ordinal In days 
Deductible Ordinal  
Number of Hospital visits Ordinal In days 
Seeing Endocrinologist  Categorical 0=no, 1=yes 
Had Renal Screening Categorical 0=no, 1=yes 
Had Retinal Screening Categorical 0=no, 1=yes 
Had Myocardial Infraction  Categorical 0=no, 1=yes. 
Is Blind  Categorical 0=no, 1=yes. 
Has End-Stage Renal Disease Categorical 0=no, 1=yes. 
Has Urinary Tract infections Categorical 0=no, 1=yes. 
LIS enrollment   Categorical 0=no, 1=yes 
Dual enrollment Categorical 0=no, 1=yes 
Controlled Blood Pressure1 Categorical 0=no, 1=yes 
  1 Blood pressure under 140 systolic and 90 diastolic 
Statistical Analysis 
Regression results were validated using the HO1 group. The final regression equation 
analysis includes looking at the individual predictor variables, checking correlations 
between the outcome and predictor variables, and the R2 value. We will use a Chi-Square 





Pearson’s correlation values tell us the direction and strength of the linear relationship 
between two variables (Warner, 2013). Pearson’s correlation values of greater than 0.5 
show significant levels of correlation between the variables. Values down to 0.3 and 
above have small correlations but still significant enough to consider in the final 
equation. Any predictor variable must have a p-value of less than 0.05 (Warner, 2013). 
Pearson’s correlations can give us some insight into the R2 value produced by regression 
analysis and are obtained by selecting a correlation from the SPSS interface and adding 
all of the variables in the analysis. 
R2 is a statistical value created by a regression analysis indicating how well the 
predictor variables match the regression line (Warner, 2013).  In human research, an R2 
value greater than 0.2 is considered adequate. This value is somewhat lower than in other 
kinds of research, but because of the effect of human behavior in the analysis, this lower 
number is acceptable (Hair et al., 2011). HbA1c level, the outcome variable in this 
analysis, is controlled by human behavior in medication compliance, following a 
recommended diet, and quantity of exercise.  
Collinearity, a type of regression interference defined as the potential for 
correlations between a predictor variable, must be determined when doing regression 
analysis.  Multicollinearity is the condition where multiple predictors interfere with the 
regression results. One assumption of regression is that all the predictor variables are 
independent of each other, and each predictor has unique information about the outcome 





the regression results and must be considered. Collinearity can cause issues where 
standard errors appear high, or a Beta weight can have a direction that makes no sense 
(Belsley, 1984). The method chosen for determining collinearity in this study is the 
Variance Inflation Factor (VIF). VIF is a measure of the degree of standard error 
inflation, where a VIF factor greater than 10 is indicative of collinearity (Weisberg, 2005, 
p. 217). Our analysis checks VIF values using the SPSS collinearity diagnostics when 
running the regression analysis.  One method of addressing collinearity issues is to 
remove a redundant variable (multiple variables predicting the same thing). Another 
method of dealing with collinearity is to aggregate redundant variables into a single 
variable (O’Brien, 2007). We used the Variance Inflation Factor to determine collinearity 
or multicollinearity to determine which variables to remove from the analysis.  
The equation for each regression analysis is the same as the fundamental equation 
for a straight line, y = mx + b, where y is the predicted HbA1c value, b is the y-axis 
intercept, and m is the coefficient for the statistically significant predictor variable. The 
final equation will take the final form of y = b + coeff1*predictor1 value + 
coeff2*predictor2 value + coeff3*predictor3 value + coeffN*predictorN value where 
each of the predictors have a significance of less than 0.05. These final equations define 
the different models from the research questions for predicting HbA1c values.  
The data that support the findings of this study are available from the corresponding 
author, but restrictions apply to the availability of these data used under license for the 





corresponding author upon reasonable request and with permission of the MCO that 
provided the data. 
Results 
The purpose of this quantitative research was to determine if there is an 
association between medication compliance, as calculated by the PDC, oral 
antihyperglycemic medication class, and HbA1c levels in Medicare individuals with type 
2 diabetes while controlling for covariates such as age, sex, financial subsidy type, 
comorbidities, hospital visits, and if they are seeing an endocrinologist. On September 29, 
2020, a large, nationwide MCO agreed to provide the use of their client data for this 
study. Approval for this study was received by the Walden University IRB, number 10-
30-20-0721525, on October 30, 2020.  Two MCO Business Analysts produced 
secondary, de-identified data compliant with HIPAA regulations using the enrollment 
criteria for the study.   
Data Collection and Cleaning 
 The initial data pull included members enrolled in a Medicare Advantage plan for 
2019, over 21, diagnosed with type 2 diabetes, and took one or a combination of the six 
antihyperglycemic medications classes.  The initial data pull included 76,586 MCO 
members. After eliminating those who had not had an HbA1c level completed during the 
2019 calendar year and those who had taken more than one of the medication classes 
either as a single class or a combination class during the year, the final count dropped to 





members, and a test group of 30%, or 6,792 members. There was an error in the 
methodology used to determine participation in the Low -Subsidy (LIS) program by the 
MCO. There were members listed in both the LIS and DSNP programs simultaneously, a 
situation that is not possible. To correct this problem a new variable in SPSS reflecting 
the correct value for anyone in the LIS program sample was created for an adjusted LIS 
variable where a member who showed in both a DSNP and LIS program was coded as in 
a DSNP program while individuals showing in a LIS plan only were coded as in a LIS 
program. We created dummy variables for the following categorical variables, region, 
sex, and medication class.  
 Finally, PDC values were mean-centered providing better understanding of the 
PDC value. In our new variables, a value of 0 indicates a real PDC value of 0.8581. This 
centering technique allowed us to better see those who were above and below the mean 
of each medication (Hayes, 2009, pp. 466-467).   
Comparing Samples 
The differences between the sample chosen for the study and the population not 
selected were examined to find any differences that might explain the lack of HbA1c 
levels. Of our total 2019 population, 76586, only 32307 had an HbA1c completed during 
the year, with a compliance rate of 42%. We examined the two groups to try to find 
evidence on why individuals did not have an HbA1c level during the year when HbA1c 





The independent samples T test from SPSS compares continuous predictors and 
the Crosstabs function for comparing categorical predictors. The independent samples T 
test is the correct test because we want to compare the means between those we included 
in our analysis and those we did not. Additionally, one group's selection did not influence 
the other group's selection (Peck et al., 2012).    
We analyzed the continuous variables age, number of visits to an Endocrinologist, 
the PDC value, and the number of hospital visits. Table 4 shows that PDC, Hospital 
visits, and Endocrinologist visits all have a Levene's Test for Equality of Variances 
significance level of less than 0.001 with equal variances not assumed. We can reject the 
null hypothesis that these predictors' means are equal and accept the alternate hypothesis 
that there are statistically significant differences in the two groups. The categorical 
HbA1c value is the grouping variable using a value 0 for no test and 1 for having an 
HbA1c level done during the measurement year, 2019.  In Table 3 the Levene’s test for 
age has a significance of 0.240; thus, we accept the null hypothesis that there are no 
statistical differences between the groups ages.  However, when we examine the T-Test 
significance values for all the predictors in their appropriate row, we see that the p values 
are all less than 0.05 and therefore, we can conclude that there are statistically significant 
differences between the two groups. 
To compare the categorical predictor values in the two groups, the crosstabs chi-
square function of SPSS is the appropriate test. The HbA1c is used as a categorical value 





Myocardial Infarction or blindness diagnosis showed no statistically significant 
differences between the no HbA1c level done and had an HbA1c level done groups. 
While there are statistically significant differences between the predictor values, there are 
too many of them, and we did not have the correct data set to determine which ones 
might contribute to better identify what differences, if any, contributed to not having an 
HbA1c level completed during the year. And this examination is beyond the scope of this 
discussion. Table 5 is a list of the predictors that show a statistically significant difference 
between the two groups.  
Table 3  
 
















EVA 141.12 0 36122 0 -0.042 -0.031 
EVNA   4417 0 -0.043 -0.0301 
Age 
EVA 1.38 0.24 36607 0 -2.075 -1.47 
EVNA   4809 0 -2.08 -1.466 
Hospital  EVA 12.95 0 36607 0.003 -0.448 -0.093 
Visits EVNA   5093 0.001 -0.433 -0.107 
Seeing 
Endocrinologist 
EVA 33.35 0 36607 0.003 0.013 0.066 
EVNA     4456 0.015 0.008 0.072 
1 rounded to an integer  
EVA - Equal variances assumed 







Table 4  











Taking Biguanide 2732 25277 88.6 0.000 0.049 
Taking Thiazolidinediones 66 559 0.001 0.978 0 
Taking DPP 171 1297 1.957 0.162 0.007 
Taking Sulfonylureas 631 4187 36.72 0.000 0.032 
Taking DPP Biguanide 135 749 20.936 0.000 0.024 
Taking Sulfonylurea 
Biguanide 100 415 42948 0.000 0.034 
Seeing Endocrinologist 186 1348 3.968 0.046 0.01 
Retinopathy screening 417 3748 2.228 0.000 0.008 
Nephropathy screening 723 7064 14.862 0.000 0.02 
BP Control 1137 11459 49.261 0.000 0.061 
End Stage Renal Disease 2693 20324 80.219 0.000 0.047 
Myocardial Infraction 257 1984 1.93 0.165 0.007 
UTI 554 5153 5.559 0.018 0.012 
Blindness 63 435 2.257 0.133 0.008 
DSNP Program 797 8939 81.13 0.000 0.047 
LIS Program 960 7319 11.354 0.001 0.018 
No Financial Subsidy 2121 16473 26.428 0.000 0.027 
 
Table 5  
 
Statistically different predictors HbA1c group vs. No HbA1c group 
 
Predictor Sig (p<0.05) 
PDC 0.0001 
Hospital Visits 0.0001 
Seeing an Endocrinologist 0.0001 
Biguanide 0.0001 
Sulfonylureas 0.0001 
DPP Biguanide 0.0001 
Sulfonylurea Biguanide 0.0001 





Retinopathy screening 0.0001 
Nephropathy screening 0.0001 
BP Control 0.0001 
End-Stage Renal Disease 0.0001 
UTI 0.018 
DSNP Program 0.0001 
LIS Program 0.001 
No Financial Subsidy 0.0001 
 
Descriptive Statistics 
We ran a set of descriptive statistics for each of the medication classes and found 
that combination classes did not have a sufficient number of members to provide 
statistical power for analysis. Table 6 is a count of members taking each class of 
medication.  
Table 6  
 
Count for each of the Classes and Combination of Classes  
 
Medication Class Count 
Biguanides 11713 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 601 
Thiazolidinediones 214 
Sulfonylureas 2554 
Meglitinide Analogues 35 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors 71 
Meglitinide-Biguanide Combination 0 
SGLT2 Inhibitor - DPP-4 Inhibitor Combinations 2 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide Combination 41 
Sulfonylurea-Biguanide Combinations 260 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide Combination 353 
Sulfonylurea-Thiazolidinedione Combination 0 
Thiazolidinedione-Biguanide Combination 1 






Using G*Power, we calculated the need for a population of at least 89 members 
for statistical power in calculations. Meglitinide Analogues, SGLT2 inhibitors, 
Meglitinide-Biguanide Combinations, SGLT2 Inhibitor - DPP-4 Inhibitor Combinations, 
Sulfonylurea-Thiazolidinedione Combinations, Thiazolidinedione-Biguanide 
Combinations, and DPP-4 Inhibitor-Thiazolidinedione Combinations were eliminated 
due to insufficient counts. Medication classes, their corresponding mean-centered PDC 
value, the region of the country in which the member lives, and sex were dummy coded. 
Tables 7 and 8 show the descriptive statistics for the group that did and the group that did 
not have an HbA1c level taken during the 2019 calendar year.  
Table 7  
 
Descriptive Statistics for Members with an HbA1c level 
 
 Min Max Mean 
Std. 
Deviation 
Biguanide 0 1 .75 .435 
DPP 0 1 .04 .194 
Thiazolidinediones 0 1 .01 .114 
Sulfonylurea 0 1 .16 .369 
Sulfonylurea Biguanide 0 1 .02 .125 
DPP Biguanide 0 1 .02 .146 
Male 0 1 .41 .492 
Age 22 101 71.1 9.38 
DSNP 0 1 .32 .466 
LIS 0 1 .22 .413 
South 0 1 .85 .354 
NE 0 1 .09 .293 
NW 0 1 .02 .134 
W 0 1 .02 .123 





HbA1c Level 4.10 15.50 6.59 0.98 
Hospital Visits 0 91 2.78 5.42 
Seeing Endocrinologist 0 1 .04 .193 
Retinopathy Screening 0 1 .10 .306 
Nephropathy Screening 0 1 .21 .408 
Blood Pressure Controlled 0 1 .94 0.2253 
End Stage Renal Disease 0 1 .49 .500 
Blindness diagnosis 0 1 .01 .112 
Myocardial Infarction diagnosis 0 1 .06 .244 
UTI diagnosis 0 1 .15 .358 
Mean Adj PDC -.77 .14 .0006 .178 
PDC Value 0.094 1.000 0.8587 0.178 
Biguanide Mean PDC -.77 .14 .0007 .152 
DPP Mean PDC -.73 .14 -.0016 .043 
Thiazolidinediones Mean PDC -.68 .14 .0003 .0192 
Sulfonylurea Mean PDC -.76 .14 .0018 .0707 
Sulfonylurea Biguanide Mean PDC -.73 .14 .0004 .0202 
DPP Biguanide Mean PDC -.70 .14 -.0008 .0292 
Count for all items is 15713 
PDC values are mean adjusted with 0. 8587 as mean value. 
 
Table 8  
 
Descriptive Statistics Members with no HbA1c level in 2019 
 
 Min Max Mean 
Std. 
Deviation 
Male 0 1 .40 .490 
Age 22 103 70.41 9.927 
DSNP 0 1 .30 .459 
LIS 0 1 .27 .443 
South 0 1 .62 .484 
NE 0 1 .28 .449 
West 0 1 .04 .187 
NW 0 1 .04 .201 





Number of Hospital Visits 0 253 5.3 8.5 
Seeing an Endocrinologist 0 1 .04 .194 
Retinopathy Screening 0 1 .06 .233 
Nephropathy Screening 0 1 .07 .250 
End Stage renal disease diagnosis 0 1 .47 .499 
Blindness diagnosis 0 1 .02 .124 
Myocardial Infarction 0 1 .07 .254 
UTI 0 1 .14 .347 
Blood Press Controlled 0 1 .16 .368 
Biguanides 0 1 .74 .436 
DPP 0 1 .05 .215 
Thiazolidinediones 0 1 .01 .117 
Sulfonylurea 0 1 .14 .348 
Sulfonylurea Biguanide 0 1 .01 .104 
DPP Biguanide 0 1 .03 .165 
Mean Adjusted PDC -.7957 .1727 -.0009 .2086 
Biguanide Mean Adj PDC -.7957 .1727 .0010 .1762 
DPP Mean Adj PDC -.7461 .1727 -.0016 .0535 
Thiazolidinediones Mean Adj PDC -.6792 .1727 .0001 .0231 
Sulfonylurea Mean Adj PDC -.7403 .1727 .0014 .0784 
Sulfonylurea Biguanide Mean Adj PDC -.7382 .1727 .0001 .0192 
DPP Biguanide Mean Adj PDC -.7775 .1727 -.0011 .0399 
PDC Value .0315 1.0000 .8263 .2086 
Count for all items is 23331 
PDC values are mean adjusted with 0.8263 as mean value 
Max PDC value of 0.1727 equals a PDC of 100% or full compliance 
 
Regression Equations 
The requirements for using multilinear regressions are a continuous outcome 
variable, categorical or continuous predictors, normally distributed residuals, no 
multicollinearity, and homoscedasticity must be present (Osborne & Waters, 2002). Our 
outcome variable, HbA1c level, is measured as a continuous variable. PDC, deductible, 





Screening, BP Controlled, Myocardial Infarction, LIS, DSNP, Thiazolidinediones, UTI, 
DPP Biguanide, End-Stage Renal Disease, Male, DPP, Nephropathy Screening, seeing an 
endocrinologist, and Sulfonylurea Biguanide are all categorical variables. We did find 
multicollinearity with the regional variable and eliminated that predictor from our 
analysis. Figure 2 shows normally distributed residuals in our data. Figure 3 verifies that 
we have homoscedasticity in our data.  














Each of the six medication classes were recoded into binary variables. There was 
sufficient sample size to include in our analysis the following medication classes, 
Biguanide, DPP, Sulfonylurea Biguanide combination, Thiazolidinediones, Sulfonylurea, 
and DPP Biguanide combination. From these regression analyses, we developed 
predictive model equations for each of these medication classes. We included all 
regression values, even if they are not statistically significant because even if a predictor 
is not statistically significant, it has clinical significance (Schober et al., 2018). These 
equations give us a model that predicts HbA1c values when switching from one 
medication class to another. Use of the equation requires user input of the new 
medication class wanted, the PDC for that class, and values for each covariate. The result 





In our first run of this analysis, we found multicollinearity among those living in 
the country's south and NE regions based on the Variance of Inflation Factor (VIF) 
values. Using a value of ten as the value to indicate a collinearity problem, the four 
regional covariates Northeast, Northwest, South, and West were removed from our 
regression analysis because of the collinearity problem.  
Table 9  
 










South 0.15 0.439 -0.23 0.529 0.04 25.156 
NE 0.308 0.118 -0.078 0.694 0.042 23.789 
 
Table 10  
 
Biguanide Medication Class as Reference Variable 
 
Model Summary b 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
1 .206a 0.043 0.039 0.88371 
a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC, Blindness, 
DPP Biguanide Mean PDC, DPP Mean PDC, Seeing Endocrinologist, Retinopathy 
Screening, Sulfonylurea Biguanide Mean PDC, BP Controlled, Myocardial 
Infarction, LIS, Thiazolidinediones, UTI, DPP Biguanide, Sulfonylurea Mean PDC, 
End-Stage Renal Disease, Male, IsDPP2, Hospital Visits, Nephropathy Screening, 
Age, Deductible, Sulfonylurea Biguanide, DSNP 
b. Dependent Variable: HbA1c level 
 
 






Coefficients with DPP as Reference 






(Constant) 7.031 0 6.829 7.232  
DPP 0.057 0.334 -0.059 0.173 1.076 
DPP Mean PDC 0.169 0.542 -0.375 0.713 1.035 
DPP Biguanide 0.191 0.021 0.029 0.353 1.024 
DPP Biguanide Mean PDC -1.231 0.006 -2.114 -0.35 1.014 
Sulfonylurea Biguanide 0.925 0 0.727 1.123 1.346 
Sulfonylurea Biguanide Mean 
PDC 
-1.797 0.039 -3.501 -0.09 1.343 
Thiazolidinedione -0.09 0.375 -0.29 0.109 1.011 
Thiazolidinedione Mean PDC -0.814 0.183 -2.013 0.385 1.003 
Sulfonylurea 0.274 0 0.212 0.336 1.084 
Sulfonylurea Mean PDC -0.27 0.112 -0.603 0.063 1.024 
Male 0.088 0 0.042 0.134 1.059 
Age -0.004 0.001 -0.007 -0 1.108 
DSNP -0.272 0 -0.393 -0.15 7.032 
LIS -0.092 0.004 -0.155 -0.03 1.228 
Deductible 0 0.003 0 0.001 6.62 
Hospital Visits -0.007 0.001 -0.012 -0 1.081 
Seeing Endocrinologist -0.071 0.208 -0.18 0.039 1.034 
Retinopathy Screening 0.045 0.189 -0.022 0.111 1.08 
Nephropathy Screening 0.005 0.832 -0.042 0.052 1.081 
End Stage Renal Disease -0.04 0.094 -0.087 0.007 1.121 
Blindness 0.168 0.078 -0.019 0.354 1.004 
Myocardial Infarction -0.031 0.504 -0.123 0.06 1.032 
UTI -0.035 0.27 -0.097 0.027 1.054 
BP Controlled -0.207 0 -0.306 -0.11 1.017 
1 95% CI 
Table 12  
 













.212a 0.045 0.041 0.88287 
a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC, 
Blindness, DPP Biguanide Mean PDC, Biguanide Mean PDC, Seeing 
Endocrinologist, Retinopathy Screening, Sulfonylurea Biguanide Mean PDC, 
BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, UTI, DPP 
Biguanide, Sulfonylurea Mean PDC, End-Stage Renal Disease, Male, 
Biguanide, Hospital Visits, Nephropathy Screening, Age, Deductible, 
Sulfonylurea Biguanide, DSNP 
 
 
Table 13  
 
Coefficients with DPP as Reference 








(Constant) 7.076 0 6.837 7.315  
Biguanide -0.05 0.389 -0.165 0.064 5.064 
Biguanide Mean PDC -0.055 0.489 -0.211 0.101 1.02 
Thiazolidinediones -0.142 0.22 -0.368 0.085 1.298 
Thiazolidinediones Mean PDC -0.814 0.183 -2.013 0.385 1.003 
Sulfonylurea 0.223 0 0.099 0.347 4.281 
Sulfonylurea Mean PDC -0.27 0.112 -0.603 0.063 1.024 
Sulfonylurea Biguanide 0.874 0 0.648 1.099 1.75 
Sulfonylurea Biguanide Mean 
PDC -1.798 0.039 -3.502 -0.094 1.343 
DPP Biguanide 0.14 0.158 -0.055 0.335 1.473 
DPP Biguanide Mean PDC -1.232 0.006 -2.116 -0.349 1.014 
Male 0.088 0 0.042 0.134 1.059 
Age -0.004 0.001 -0.007 -0.002 1.109 
DSNP -0.268 0 -0.39 -0.146 7.03 
LIS -0.092 0.004 -0.155 -0.029 1.226 
Deductible 0 0.004 0 0.001 6.639 
Hospital Visits -0.008 0.001 -0.012 -0.003 1.08 
Seeing Endocrinologist -0.07 0.21 -0.18 0.04 1.034 
Retinopathy Screening 0.044 0.19 -0.022 0.111 1.08 





End Stage Renal Disease -0.039 0.1 -0.086 0.008 1.121 
Blindness 0.168 0.077 -0.018 0.354 1.004 
Myocardial Infarction -0.031 0.505 -0.122 0.06 1.032 
UTI -0.035 0.263 -0.097 0.027 1.054 
BP Controlled -0.205 0 -0.304 -0.107 1.019 




Table 14  
 
Sulfonylurea Biguanide Reference Model Summary b 
Model R R Square 
Adjusted 
R Square 
Std. Error of the 
Estimate 
1 .212a 0.045 0.041 0.88287 
a. Predictors: (Constant), Sulfonylurea, Thiazolidinediones Mean PDC, 
Blindness, DPP Biguanide Mean PDC, Biguanide Mean PDC, Seeing 
Endocrinologist, Retinopathy Screening, DPP Mean PDC, BP Controlled, 
Myocardial Infarction, LIS, Thiazolidinediones, UTI, DPP Biguanide, 
Sulfonylurea Mean PDC, End-Stage Renal Disease, Male, Biguanide, 
Hospital Visits, Nephropathy Screening, Age, Deductible, DPP, DSNP, 
LIS 
 
b. Dependent Variable: HbA1c continuous value 
 
Table 15  
 
Coefficients Sulfonylurea Biguanide Reference  






(Constant) 7.847 0 7.581 8.113  
Biguanide -0.819 0 -0.991 -0.648 11.358 
Biguanide Mean PDC -0.055 0.491 -0.211 0.101 1.02 
DPP -0.763 0 -0.966 -0.559 3.31 
DPP Mean PDC 0.17 0.541 -0.374 0.714 1.035 
Thiazolidinediones -0.911 0 -1.171 -0.65 1.719 
Thiazolidinediones Mean PDC -0.814 0.184 -2.013 0.386 1.003 





Sulfonylurea Mean PDC -0.271 0.111 -0.604 0.062 1.024 
DPP Biguanide -0.629 0 -0.862 -0.396 2.114 
DPP Biguanide Mean PDC -1.232 0.006 -2.115 -0.348 1.014 
Male 0.088 0 0.042 0.135 1.059 
Age -0.004 0.001 -0.007 -0.002 1.11 
DSNP -0.275 0 -0.397 -0.153 7.033 
LIS -0.095 0.003 -0.158 -0.032 1.228 
Deductible 0 0.003 0 0.001 6.629 
Hospital Visits -0.007 0.001 -0.012 -0.003 1.081 
Seeing Endocrinologist -0.072 0.198 -0.182 0.038 1.034 
Retinopathy Screening 0.046 0.172 -0.02 0.113 1.079 
Nephropathy Screening 0.007 0.765 -0.04 0.054 1.084 
End Stage Renal Disease -0.04 0.09 -0.087 0.006 1.121 
Blindness 0.167 0.08 -0.02 0.353 1.004 
Myocardial Infarction -0.031 0.503 -0.123 0.06 1.032 
UTI -0.035 0.266 -0.097 0.027 1.054 




Model Summary b 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .212a 0.045 0.041 0.88287 
a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, DPP Biguanide 
Mean PDC, DPP Mean PDC, Sulfonylurea Mean PDC, Biguanide Mean PDC, 
BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, UTI, Seeing 
Endocrinologist, DSNP, LIS, DPP Biguanide, Age, Male, DPP, Sulfonylurea, 
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC 
b. Dependent Variable: HbA1c level 
 
Table 17  
 
Coefficients Thiazolidinediones as Reference a 
  










(Constant) 6.929 47.12 0 6.641 7.218   
DPP 0.154 1.326 0.185 -0.073 0.381 4.117 
DPP Mean PDC 0.169 0.609 0.543 -0.375 0.713 1.035 
DPP Biguanide 0.288 2.215 0.027 0.033 0.542 2.52 
DPP Biguanide Mean 
PDC 
-1.231 -2.73 0.006 -2.114 -0.347 1.014 
Sulfonylurea Biguanide 1.021 7.184 0 0.742 1.299 2.668 
Sulfonylurea Biguanide 
Mean PDC 
-1.797 -2.067 0.039 -3.501 -0.093 1.343 
Sulfonylurea 0.37 3.535 0 0.165 0.576 11.77 
Sulfonylurea Mean PDC -0.27 -1.592 0.111 -0.603 0.063 1.024 
Biguanide 0.097 0.954 0.34 -0.102 0.297 15.41 
Biguanide Mean PDC -0.055 -0.691 0.49 -0.211 0.101 1.02 
Male 0.089 3.775 0 0.043 0.135 1.059 
Age -0.004 -3.321 0.001 -0.007 -0.002 1.11 
DSNP -0.271 -4.354 0 -0.393 -0.149 7.042 
LIS -0.093 -2.911 0.004 -0.156 -0.031 1.229 
Deductible 0 2.951 0.003 0 0.001 6.64 
Hospital Visits -0.008 -3.37 0.001 -0.012 -0.003 1.081 
Seeing Endocrinologist -0.07 -1.241 0.215 -0.179 0.04 1.034 
Retinopathy Screening 0.044 1.303 0.193 -0.022 0.111 1.08 
Nephropathy Screening 0.006 0.249 0.803 -0.041 0.053 1.085 
End Stage Renal Disease -0.04 -1.664 0.096 -0.086 0.007 1.121 
Blindness 0.168 1.772 0.076 -0.018 0.355 1.004 
Myocardial Infarction -0.032 -0.686 0.493 -0.123 0.059 1.032 
UTI -0.035 -1.113 0.266 -0.097 0.027 1.054 
BP Controlled -0.206 -4.085 0 -0.305 -0.107 1.019 
 
 
Table 18  
 
Sulfonylurea Model Summary b 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 





a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, DPP Biguanide 
Mean PDC, DPP Mean PDC, Thiazolidinediones Mean PDC, Biguanide 
Mean PDC, BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, 
UTI, Seeing Endocrinologist, DSNP, LIS, DPP Biguanide, Age, Male, DPP, 
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC 
b. Dependent Variable: HbA1c level 
 
Table 19  
 
Coefficients Sulfonylurea as Reference a 
  






(Constant) 7.293 66.184 0 7.077 7.509 
 
DPP -0.21 -3.298 0.001 -0.336 -0.085 1.25 
DPP Mean PDC 0.169 0.608 0.543 -0.375 0.713 1.035 
DPP Biguanide -0.08 -0.875 0.381 -0.246 0.094 1.125 
DPP Biguanide Mean 
PDC 
-1.23 -2.732 0.006 -2.115 -0.348 1.014 
Sulfonylurea 
Biguanide 
0.658 6.323 0 0.454 0.862 1.43 
Sulfonylurea 
Biguanide Mean PDC 
-1.8 -2.069 0.039 -3.503 -0.094 1.343 
Biguanide -0.27 -8.446 0 -0.328 -0.204 1.478 
Biguanide Mean PDC -0.05 -0.682 0.495 -0.21 0.102 1.02 
Thiazolidinedione -0.36 -3.416 0.001 -0.563 -0.152 1.068 
Thiazolidinedione 
Mean PDC 
-0.82 -1.331 0.183 -2.014 0.385 1.003 
Male 0.088 3.729 0 0.042 0.134 1.058 
Age -0 -3.329 0.001 -0.007 -0.002 1.11 
DSNP -0.27 -4.339 0 -0.392 -0.148 7.044 
LIS -0.09 -2.865 0.004 -0.155 -0.029 1.228 
Deductible 0 2.949 0.003 0 0.001 6.64 
Hospital Visits -0.01 -3.293 0.001 -0.012 -0.003 1.079 
Seeing Endocrinologist -0.07 -1.244 0.213 -0.18 0.04 1.034 
Retinopathy Screening 0.045 1.312 0.19 -0.022 0.111 1.08 
Nephropathy Screening 0.005 0.217 0.828 -0.042 0.052 1.084 
End Stage Renal 
Disease 





Blindness 0.167 1.757 0.079 -0.019 0.353 1.004 
Myocardial Infarction -0.03 -0.672 0.502 -0.123 0.06 1.032 
UTI -0.04 -1.11 0.267 -0.097 0.027 1.054 
BP Controlled -0.21 -4.091 0 -0.305 -0.107 1.019 
 
 
Table 20  
 
DPP Biguanide Model Summary b   
Model R R Square Adjusted R Square 
Std. Error of 
the Estimate 
1 .212a 0.045 0.041 0.88287 
a. Predictors: (Constant), Sulfonylurea Biguanide Mean PDC, Sulfonylurea 
Mean PDC, DPP Mean PDC, Thiazolidinediones Mean PDC, Biguanide 
Mean PDC, BP Controlled, Myocardial Infarction, LIS, Thiazolidinediones, 
UTI, Seeing Endocrinologist, DSNP, LIS, Sulfonylurea, Age, Male, DPP, 
Hospital Visits, Deductible, Sulfonylurea Biguanide, Biguanide, Mean PDC 
b. Dependent Variable: HbA1c level  
 
DPP Biguanide Model Summary b   






1 .212a 0.045 0.041 0.88287 
a. Predictors: (Constant), Sulfonylurea Biguanide Mean 
PDC, Sulfonylurea Mean PDC, DPP Mean PDC, 
Thiazolidinediones Mean PDC, Biguanide Mean PDC, 
BP Controlled, Myocardial Infarction, LIS, 
Thiazolidinediones, UTI, Seeing Endocrinologist, 
DSNP, LIS, Sulfonylurea, Age, Male, DPP, Hospital 
Visits, Deductible, Sulfonylurea Biguanide, Biguanide, 
Mean PDC 
b. Dependent Variable: HbA1c level  
 
Table 21  












(Constant)   55.155 0 6.99 7.505   
IsDPP2 -0.034 -1.578 0.115 -0.352 0.038 3.036 
DPP Mean PDC 0.008 0.616 0.538 -0.373 0.715 1.035 
Sulfonylurea 
Biguanide 
0.102 5.502 0 0.457 0.962 2.195 
Sulfonylurea 
Biguanide Mean PDC 
-0.03 -2.067 0.039 -3.503 -0.093 1.343 
Biguanide Mean PDC -0.009 -0.685 0.493 -0.211 0.101 1.02 
Biguanide -0.103 -2.6 0.009 -0.376 -0.053 10.085 
Thiazolidinediones -0.038 -2.351 0.019 -0.559 -0.051 1.637 
Thiazolidinediones 
Mean PDC 
-0.017 -1.327 0.184 -2.012 0.388 1.003 
Sulfonylurea 0.024 0.683 0.495 -0.111 0.229 8.021 
Sulfonylurea Mean 
PDC 
-0.02 -1.592 0.111 -0.604 0.063 1.024 
Male 0.048 3.772 0 0.043 0.135 1.059 
Age -0.044 -3.342 0.001 -0.007 -0.002 1.11 
DSNP -0.146 -4.396 0 -0.396 -0.152 7.04 
LIS -0.041 -2.953 0.003 -0.158 -0.032 1.228 
Deductible 0.095 2.954 0.003 0 0.001 6.641 
Hospital Visits -0.044 -3.374 0.001 -0.012 -0.003 1.081 
Seeing 
Endocrinologist 
-0.016 -1.256 0.209 -0.18 0.039 1.034 
Retinopathy 
Screening 
0.017 1.289 0.197 -0.023 0.11 1.08 
Nephropathy 
Screening 
0.003 0.205 0.837 -0.042 0.052 1.085 
End Stage Renal 
Disease 
-0.022 -1.689 0.091 -0.087 0.006 1.121 
Blindness 0.022 1.771 0.077 -0.018 0.355 1.004 
Myocardial Infarction -0.009 -0.685 0.493 -0.123 0.059 1.032 
UTI -0.014 -1.104 0.269 -0.097 0.027 1.054 







Using these regression results to create equations for each medication class, one of the medication 
classes as a reference variable and left out of the analysis. Running the DPP to Biguanide 
regression to determine how well the equation predicted biguanide levels there were 1925 
members from the test list on a biguanide medication used as our base group.  Both sets of data 
showed normal distributions—however, significant differences in minimum and maximum values 
as seen in figures 4 and 5.  
 








Figure 5  




There were statistically significant differences between the actual and predicted HbA1c levels,  as 
demonstrated in Table 22. Kurtosis analysis shows that the predicted values have a different 
distribution of values at the distribution tails, and we see this in the predictive values. The ends of 
the distribution are much lower values than those in the actual data.  Table 23 shows the SPSS 
interclass correlation function results with the two-way mixed model and absolute agreement 
selected. The two-way mixed model is appropriate for this analysis because there is a randomly 
selected sample, the values are fixed, and we selected absolute agreement because we want to see 
how well the regression can predict an HbA1c values. There is very little correlation between 
either single or average measure tests. Finally, there is no statistically significant correlations as 
the p-value for the average measurements was 0.088. 
Table 22  
HbA1c Actual vs. Predicated 
 HbA1cValue Predicted 





Missing 0 0 
Mean 6.502 5.776 
Median 6.300 5.800 
Std. Deviation 0.8686 0.1767 
Skewness 2.587 0.167 
Std. Error of Skewness 0.056 0.056 
Kurtosis 12.480 0.551 
Std. Error of Kurtosis 0.112 0.112 
Minimum 4.2 5.1 
Maximum 14.7 6.7 
 
Table 23  
 











Bound Value df1 df2 Sig 
Single 
Measures 
.031a -0.014 0.075 1.064 1924 1924 0.088 
Average 
Measures 
.060c -0.028 0.140 1.064 1924 1924 0.088 
Two-way mixed-effects model where people effects are random and measures 
effects are fixed. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. 
The between-measure variance is excluded from the denominator variance. 
c. This estimate is computed assuming the interaction effect is absent because 
it is not estimable otherwise. 
 
Discussion 
Data analysis answered both research questions in the affirmative, that in making 





medication and patient compliance rate is important. Research question one asks if there 
is a relationship between PDC calculated for individual antihyperglycemic class of 
medications and HbA1c values in Medicare MCO members with type 2 diabetes while 
controlling for age, sex, LIS enrollment, DSNP enrollment, and seeing an 
endocrinologist?  Research question two asks if there is a relationship between PDC 
index calculated for individual, commercially available combination, antihyperglycemic 
class of medications and HbA1c values in Medicare MCO members with type 2 diabetes 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, 
LIS enrollment, and DSNP enrollment?  Figure 6 is a simple slopes graph looking at the 
relationship between the reported HbA1c level and the mean adjusted PDC (the zero 
value is a PDC of 85%) for each of the medication classes with a sufficient sample 





Figure 6  
HbA1c Simple Slopes 
 
Table 24  
 
Simple slope Equation and R2 
  
Medication Class Equation R2 Value 
Biguanide y = 6.53 - 0.16*x 0.057 
DPP y = 6.48 – 0.09*x 0.024 
DPP-Biguanide y = 6.78 - 0.94*x 0.699 
Thiazolidinediones   y = 6.4 - 0.83*x 0.632 
Sulfonylurea y = 6.82 - 0.25*x 0.128 
Sulfonylurea-Biguanide y = 7.4 - 2.49*x 0.914 
X=mean centered PDC value 
  
R2 values are given as a percent, range from 0% to 100%, and indicate the degree of 
correlation between the predicted HbA1c value and the actual HbA1c value. Generally, 





and the predicted HbA1c values. Low R2 values, less than 0.25, indicate low effect size, 
less than 0.255 indicate medium effect size, and above 0.75 are related to a high effect 
size (Hair et al., 2011). Figure 6 demonstrates that at high levels of compliance, above 
85%, there is not a significant difference in HbA1c values. However, as compliance rates 
drop, there is a difference in medication effectiveness on HbA1c levels. Three of the 
medication classes showed poor predictive value based on the data, Biguanide, DPP, and 
Sulfonylurea, all with R2 values less than 0.25. Showing mean to high predictive value 
were DPP-Biguanide, Thiazolidinediones, and the Sulfonylurea Biguanide combinations.  
The Sulfonylurea Biguanide combination showed the highest R2 value at 0.914.  
 An analysis of the regression equations showed that they did not fit well. The 
DPP to Biguanide and Thiazolidine to DPP Biguanide regressions were performed using 
the reliability analysis function of SPSS. Neither of the predicted values was close to the 
actual HbA1c values with p values = 0.088. One explanation for this failure to predict 
HbA1c levels accurately is due to the inability to correlate the HbA1c level and 
medication compliance.  
Clinical Indications of this Study 
 This preliminary study examines the potential association between the PDC and 
medication class and its effect on HbA1c levels. The results support the hypothesis that a 
provider must consider medication compliance rates when selecting an oral 
antihyperglycemic medication. For example, figure 6 demonstrates that for patients who 





not be the best therapeutic route considering the higher HbA1c levels at lower 
compliance rates compared to the other medications. The DPP class of medications 
shows consistent HbA1c control across all PDC values with a slope of only 0.09 (this 
means that for each unit increase in compliance, HbA1c drops by 0.09). Assuming no 
effect from medication side effects, the DPP class may be best for controlling HbA1c as 
it is not as affected by PDC as the other medication classes. However, these conclusions 
can only be used to show that a relationship exists between medication compliance, the 
class of medication taken, and medication compliance. A detailed study of this is needed 
because the precisely relationship between the HbA1c level was completed compared to 
when the medication was taken cannot be established. 
 While this study showed little statisticaly significance with low R2 values,  it does 
demonstrate clinically significant differences in the associations between OAMC, PDC 
and HbA1c levels.  Schober et al., (2018), discusses differences in core temps post-
surgery.  The authors said:  
  
“Researchers need to define and to support what they consider a minimal 
clinically important effect, and journal editors, reviewers, and readers need 
to assess whether this seems reasonable. Note that an important effect does 
not necessarily have to be large. For example, a small effect on mortality 
can make a huge difference not only for individual patients but also for 
society if a large percentage of patients is affected by the condition.”  
 
Finally, in coversations with my my personal physician and Justin Zaghi, 
Medical Director for Heal and Board Certified Internist, about what they consider 





medication would be considered significant by them (J. Zaghi, S. Hartl, personal 
communication, January 2021).    
 
Limitations of the Study 
Several biases arise with this study. Because we only had data on Medicare 
Advantage individuals, the results are limited to people with type 2 diabetes and in a 
Medicare Advantage plan.  Because we had a large group that did not have an HbA1c 
level completed, our results might be biased towards those who are overall more 
compliant, i.e., if they had an HbA1c level done then they could be more compliant 
towards their medication consumption.  These results are of interest because both groups 
showed average medication compliance rates of over 80%.   These findings are different 
from previously published studies indicating that people with diabetes are around 50% 
compliant with the medications (Wang et al., 2013). Second, we are not able to directly 
relate medication compliance with exact HbA1c draw dates. Therefore, we have to 
interpret the data with caution; however, what is shown by the data is that our hypothesis 
that providers must consider both the medication and compliance rate when making 
therapeutic decisions is valid. Finally, because we could not relate the HbA1c level to 
particular medications, we had to remove those who took more than one 
antihyperglycemic medication during the year. This data is preliminary, and our results 
should be considered with caution. Better controlled studies where HbA1c levels can 





study only looks at those on single medication therapy. Many people with diabetes take 
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Individual medication nonadherence costs for each type 2 diabetic are approximately 
$28,000 per year. Costs are the second most common reason for individual type 2 
diabetic medication nonadherence, with one in four Americans having difficulty paying 
for their medications. As a result, Medicare instituted the Low-Income Subsidy (LIS) 
program and a Dually Eligible Special Need Program (DSNP) to improve medication 
compliance through reduced financial burden. The purpose of this study is to determine 
whether financial assistance programs improve medication compliance, as calculated by 
the Proportion of Days Covered (PDC), or HbA1c levels in people with type 2 diabetes. 
This is a longitudinal retrospective study utilizing secondary claims data from a large 
nationwide Managed Care Organization with a sample size of 23,000. Linear regression 
analysis identified the effects of Low-Income Subsidy (LIS) and Dually Eligible Special 
Needs Program (DSNP) programs combined with medication compliance on lowering 
HbA1c levels. While both LIS and DSNP programs have statistically significant effects 
on HbA1c levels and medication compliance, their overall effect is minimal, with R2 
values below 1%, indicating that their goal of improving health status has not been met. 
These findings indicate that a review of the LIS and DSNP program's goal of improving 






 Diabetes is the seventh leading cause of death in the US, affecting 34 million 
diagnosed people with diabetes and another 88 million with prediabetes (Centers for 
Disease Control and Prevention, 2020). Additionally, some individuals do not know that 
they have diabetes, and many physicians are unsure of what indicates prediabetes 
(National Institute of Diabetes and Digestive and Kidney Diseases, 2017; Tseng et al., 
2017). One out of four dollars spent on healthcare in the US is spent on diabetes or any of 
the comorbidities associated with diabetes, including heart disease, stroke, nephropathies, 
and retinopathies (National Institute of Diabetes and Digestive and Kidney Diseases, 
2018; Riddle & Herman, 2018).    
Medication compliance in individuals with diabetes is an important part of their 
therapeutic regimen (Huang et al., 2018).  One issue that faces those with diabetes is the 
cost of antihyperglycemic medications (Kang et al., 2018; Kennedy-Martin et al., 2017).  
Lower compliance rates in those with diabetes result in lower health statuses and increase 
morbidity and mortality. People with diabetes are notoriously non-compliant, and in their 
first year after diagnosis, almost half missed 80% of their doses (Cramer, 2004). 
Medication compliance is a complex issue requiring patients to purchase and take their 
medications on a prescribed dosing schedule.  
Individuals with diabetes and lower socioeconomic statuses have higher 
medication non-compliance (Nam et al., 2011). One way to increase compliance is to 





reduces the number of non-compliant patients by 30%, which can be offset by reducing 
medical costs such as hospitalizations (Zeng et al., 2010).  Income and asset-based 
subsidy programs are a tool for improving medication compliance, reducing overall 
medical costs, and improving health statuses. There are two subsidy programs that 
Medicare implemented intending to improve medication compliance. Low-Income 
Subsidy (LIS) programs are for those in Medicare Part D programs and Dually Eligible 
Special Needs Programs are for those who qualify for both Medicare and Medicaid. Both 
programs are administered by Managed Care Organizations (MCO) and are not available 
with traditional Medicare.  
The 2018 Medicare Modernization Act created the LIS program and covered 4.7 
million enrollees. This program subsidized Part D for prescription costs, premiums, 
deductibles, and coinsurance (Centers for Medicare & Medicaid Services, n.d.). The 
program is part of the Medicare Extra Help initiative, where those participating must 
have a monthly income of less than $1650 for individuals and $2,175 for couples, and 
they must have limited assets. The LIS program is only available to those in a Medicare 
Advantage plan and is not available to traditional Medicare patients.  The LIS program 
eliminates Part D's donut hole provision, a gap in coverage lying between initial coverage 
limits and the catastrophic-coverage threshold as determined by the MCO. The purpose 
of the LIS program is to reap the benefits of lower overall medical costs through 





Both copays and deductibles add to health inequalities and lower medication 
adherence rates. While the LIS program attempted to address some of the issues around 
health inequalities, there are still problems. While the program subsidizes lower copays 
and premiums, deductibles may be higher, and there may be limited medication coverage 
depending on the MCO formulary.  
The DSNP program is a set of special needs programs implemented by Congress 
in 2003 based on Medicaid enrollment, income, and asset levels, with the first DSNP 
program started in 2006. In 2013, the Affordable Care Act (ACA) modified DSNP 
programs to require that MCO’s have a contract with State Medicaid plans to improve the 
integration of Medicare and Medicaid benefits. The ACA set up a list of eight elements 
state Medicaid programs must include to maintain DSNP participation eligibility 
(Archibald et al., 2019).   
Medicare is considered the primary payor, and Medicaid is the secondary payor 
for DSNP programs. Additionally, services not covered by Medicare may be covered by 
Medicaid for DSNP enrollees. Individual states set the income and asset limits, but it is 
generally a requirement that the enrollee’s income is below the poverty level, currently 
set between $12,760 and $44,120, depending on the number of individuals in the 
household (U.S. Department of Health and Human Services, 2020).  Asset limitations 
also apply.  
 A 2018 Health and Human Services report documented the relationship between 





being a part of the SDOH (Sorbero et al., 2018). DSNP programs set income 
requirements at or below the poverty level, and LIS programs are generally from the 
poverty level to 300% of the poverty level. Therefore, we have three sets of income 
levels, and we treat these as a categorical variable in this study. The categorical income 
variable comprises those not participating in an assistance program at the first level of 
income, LIS at the second with a value of 100% to 300% of the poverty level, and DSNP 
enrollees being at the third level of income, either at or below the poverty level. Having 
actual income levels would have been a better approach, but the MCO does not collect 
income data.  
Research Design and Methods 
According to Creswell and Creswell, 2017, a quantitative approach is used when a 
researcher tries to establish relationships between variables. The purpose of this study is 
to examine the relationship between enrollment in a financial assistance program and 
medication compliance in one of six classes of antihyperglycemic medications and 
HbA1c levels. Ideally, an individual with diabetes should have an HbA1c level below 
6.5%, the threshold for a diagnosis of diabetes (American Diabetes Association, 2018). 
Covariates for this study include age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural counties. The research questions for this 
manuscript are: 
RQ3: Is there a relationship between the type of subsidy plan enrollment (LIS or DSNP), 





antihyperglycemic medications on HbA1c levels in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and 
living in Urban or Rural County?   
H013: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Biguanide class of medications, and HbA1c levels in Medicare type 2 diabetics 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, and living in Urban or Rural County. 
H113: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Biguanide class of medications, both individually and in combination, and HbA1c 
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County. 
H014: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications, both individually 
and in combination, and HbA1c levels in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 





H114: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications, and HbA1c levels 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, and living in Urban or Rural County. 
H015: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Thiazolidinedione class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural County.  
H115: There is a statistically significant relationship the type of subsidy plan 
enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Thiazolidinedione class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural County.  
H016: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications, and 
HbA1c levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 






H116: There is a statistically significant relationship the type of subsidy plan 
enrollment (LIS or DSNP), PDC Medication Compliance rate for the Sodium-
Glucose Co-Transporter 2 (SGLT2) Inhibitors class of medications, and HbA1c 
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County.  
H017: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylureas class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural County.  
H117: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylureas class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural County.  
H018: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Meglitinide Analogues class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 





H118: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Meglitinide Analogues class of medications, and HbA1c levels in Medicare type 2 
diabetics while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, and living in Urban or Rural County. 
RQ 4: Is there a relationship between the type of subsidy plan enrollment (LIS or DSNP), 
PDC Medication Compliance rate for one of the six classes of combined 
antihyperglycemic medications, and HbA1c levels in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and 
living in Urban or Rural County?   
H019: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate  for the 
Meglitinide-Biguanide Combinations class of medications, and HbA1c levels in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, and living in Urban or Rural County. 
H119: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Meglitinide-Biguanide Combinations class of medications, both individually and 
in combination, and HbA1c levels in Medicare type 2 diabetics while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, and living 





H020: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the SGLT2 
Inhibitor - DPP-4 Inhibitor Combinations class of medications, both individually 
and in combination, and HbA1c levels in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, and living in Urban or Rural County. 
H120: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the SGLT2 
Inhibitor - DPP-4 Inhibitor Combinations class of medications, and HbA1c levels 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, and living in Urban or Rural County. 
H021: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications, and 
HbA1c levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County.  
H121: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sodium-Glucose Co-Transporter 2 Inhibitor-Biguanide class of medications, and 





diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County.  
H022: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylurea-Biguanide class of medications, and HbA1c levels in Medicare type 
2 diabetics while controlling for age, sex, diabetes diagnosis time, length of time 
in MCO, Plan type, and living in Urban or Rural County.  
H122: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylurea-Biguanide class of medications, and HbA1c levels in Medicare type 
2 diabetics while controlling for age, sex, diabetes diagnosis time, length of time 
in MCO, Plan type, and living in Urban or Rural County.  
H023: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Dipeptidyl Peptidase-4 Inhibitor-Biguanide class of medications, and HbA1c 
levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County.  
H123: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 





levels in Medicare type 2 diabetics while controlling for age, sex, diabetes 
diagnosis time, length of time in MCO, Plan type, and living in Urban or Rural 
County.  
H024: There is no statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylurea-Thiazolidinedione class of medications, and HbA1c levels in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, and living in Urban or Rural County.  
H124: There is a statistically significant relationship between the type of subsidy 
plan enrollment (LIS or DSNP), PDC Medication Compliance rate for the 
Sulfonylurea-Thiazolidinedione class of medications, and HbA1c levels in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, and living in Urban or Rural County. 
Longitudinal studies are done over time, with data collection done at different 
times during the study period, while retrospective studies look at past events. The sample 
was taken from 2019 claims data of those enrolled in a large nationwide MCO in this 
study with a size of 23,000 participants. Using G*Power, version 3.1.9.4, an effect size of 
0.15, an alpha error probability of 0.05, a power of 0.95, the recommended sample size is 
89. In a meta-analysis of medication compliance studies with different diseases, including 
diabetes, the authors found that studies with more than 85 participants had high statistical 





with p < 0.0001. Based on this meta-study, a value of 0.15 was used (Foot et al., 2016). 
G* Power's effect size quantifies the differences between the test and control groups 
(Cunningham & McCrum-Gardner, 2007). We selected participants who have taken only 
one of the six classes of antihyperglycemic medications during 2019 and who have had 
an HbA1c level done during the year. We excluded individuals who may have taken 
more than one medication class because we cannot associate an HbA1c level draw times 
when multiple medications are taken.  
The study population was selected from a large nationwide MCO claims database 
and include members of the MCO who are: 
1. Over 21 
2. Have type 2 diabetes 
3. Enrolled in either a Medicare Advantage (MA) or Prescription Drug Plan 
(PDP) in 2019 
4. Took only one of the six classes of antihyperglycemic medications or a 
combination of classes.  
 
All the data provided by the MCO were deidentified before release to the researcher. 
Each member was assigned a unique serial number that is part of the released data. After 
analysis, if the MCO wants to do further studies, the research data can be mapped back to 
individual members with an assigned serial number. 
Type 2 diabetes diagnoses were coded according to the ICD-10 World Health 
Organization International Statistical Classification of Diseases and Related Health using 
E11.8. Claim data will be chosen from pharmacy dispensing records, and the medication 
start date is the date of the first antihyperglycemic medication dispensing. The PDC 





Linear regressions were performed on each research question.  We split our 
sample into a learning group consisting of 70% of our total sample and a testing group 
consisting of 30% of the total sample using a split-sample validation technique (Pang & 
Jung, 2013). The learning group, L1, is the sample we used to develop the model, and the 
test group, HO1, is the one we used to test the model. We analyzed the predicted HbA1c 
values with the actual HbA1c values using a Chi-Square test.  
One potential interference with regression analysis is collinearity. In regressions, 
each predictor must identify a unique effect on the outcome variable. In this study, we 
address the issue of collinearity in two different ways. Using the SPSS linear regression 
analysis, an absolute value greater than 0.8 indicates collinearity between predictors. 
In the SPSS regression we utilized the Collinearity diagnostics function to provide 
a Variance Inflation Factor (VIF). VIF is a measure of the degree of standard error 
inflation, where a VIF factor greater than 10 is indicative of collinearity (Weisberg, 2005, 
p. 217). For this study, the unit of analysis is the member.  
Table 25 is a listing of the data variables and data types used in the analysis. 
Table 25  
Predictor Variables, their type, and possible values 
 
Variable Name Variable Type Possible Values 
Unique member identifier. Nominal Format TBD by MCO 
Age Continuous 21-100 
Sex Categorical 0=male,1=female 
HBA1c level Continuous actual level 
Deductible Continuous 0 - 410 
Medication Class Ordinal 1-35 
Medication PDC Continuous 0-1 





In LIS program Nominal 0=no, 1=yes 
Plan type Categorical 1=PDP, 2=MA + PDP 
Had Myocardial Infraction Nominal 0=no, 1=yes. 
Is Blind Nominal 0=no, 1=yes. 
Has End-Stage Renal Disease Nominal 0=no, 1=yes. 
Has Urinary Tract infections Nominal 0=no, 1=yes. 
Income Indicator Categorical 0=DSNP, 1=LIS, 3=Neither 
 
The predictive model equation will be determined by picking the predictors with a 
p-value is < 0.05. The equations for each of the research questions will be created by 
using the fundamental equation for a straight line, y = mx + b, where y is the HbA1c 
value, b is the y-axis intercept, and m is the coefficient for a statistically significant 
predictor variable. The final equation will take the final form of y = b + 
coeff1*predictor1 value + coeff2*predictor2 value + coeff3*predictor3 value + 
coeffN*predictorN value. The direction and strength of a linear relationship between two 
variables can be determined by Pearson’s correlation (Warner, 2013). Values greater than 
0.5 show significant levels of correlation between the variables. Values approaching 0.3 
have small correlations but still significant enough to consider in the final equation. Any 
predictor variable used must have a p-value of less than 0.05. Pearson’s correlations can 
give us some insight into the R2 value produced by regression analysis because it gives us 
a feeling for the strength of effect (Hair et al., 2011). Pearson’s correlation values are 
obtained by selecting a correlation from the SPSS interface and adding in all of the 
variables in the analysis. 
R2 is a statistical value created by a regression analysis indicating how well the 





indicates the quality of the fit of the data to the line created by the regression. In human 
research, an R2 value greater than 0.2 is considered adequate. This value is somewhat 
lower than in other kinds of research, but because human behavior is included in the 
analysis, this lower number is acceptable (Hair et al., 2011). Plots of the data are 
necessary to determine bias in the data. If the data is evenly dispersed around the 
regression line, then linear regression is appropriate. If the data is not evenly dispersed, 
then a non-linear approach is better (Warner, 2013).  
Results 
The purpose of this quantitative research was to determine the effect of Medicare 
DSNP or LIS programs on medication compliance or HbA1c levels in people with type 2 
diabetes while controlling for covariates such as age, sex, comorbidities, hospital visits, 
and if they are seeing an endocrinologist. On September 29, 2020, a large, nationwide 
MCO provided, and corporate compliance approved the use of their data. Approval for 
this study was received from the Walden University IRB, number 10-30-20-0721525, on 
October 30, 2020. Two MCO Business Analysts produced de-identified, secondary 
claims data.   
Sample Selection 
Our analysis included a total population of 15,713. Of that population, 4995 are in 
a DSNP program, and 3434 are in a LIS program.  The study group included members 
over 21, have only taken 1 of the oral antihyperglycemic medication classes in 2019, and 





an issue in the MCO data on how LIS and DSNP program participation was determined. 
When members went from a LIS program to a DSNP program, the system did not remove 
them from the LIS program, so our data showed them in both programs. To correct this, 
we created a new adjusted LIS variable where members who were in both programs were 
shown as in the DSNP program only.  
A mean centering technique was used to better understand the PDC values 
(Hayes, 2009, pp. 466-467).  A mean adjusted PDC was created by taking the individual 
PDC value and subtracting the overall mean PDC of 0.8583. A not in a subsidy program 
dummy variable was used as the reference variable for the in a LIS, DSNP, or no 
financial aid predictor.  
Because of insufficient members taking the Meglitinide Analogues, SGLT2 
inhibitors, Meglitinide-Biguanide Combinations, SGLT2 Inhibitor - DPP-4 Inhibitor 
Combinations, Sulfonylurea-Thiazolidinedione Combinations, Thiazolidinedione-
Biguanide Combinations, and DPP-4 Inhibitor-Thiazolidinedione Combinations, we 
eliminated these medication classes from our data. Table 26 is a count of the members 
taking each of the classes used in the study. 
Table 26  
 
Count for each of the Classes and Combination of Classes  
 
Medication Class Count 
Biguanides 11743 
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 615 
Thiazolidinediones 208 
Sulfonylureas 2559 





Dipeptidyl Peptidase-4 Inhibitor-Biguanide Combinations 340 
 
Two multiple regressions were run on the data. The first one looked at the effect 
of being in a LIS or DSNP program on HbA1c levels. The second one looked at the effect 
of being in either program on the interaction between PDC and medication class. Our 
first two regressions indicated that LIS and DSNP programs have a statistically 
significant effect on HbA1c levels and PDC. However, the R2 values were minimal and 
insignificant, 0.3% for HbA1c levels and 0.5% for overall PDC.  Our final regression 
analysis for each medication class's mean adjusted PDC values again showed statistical 
significance but insignificant R2 values. Tables 27 and 28 are the HbA1c regression 
analysis results, and Table 29 is the individual mean adjusted PDC regressions R2 values 
and regression results.  We did not include any of the covariates in our analysis because 
of the low R2 values we found when running regressions on the programs alone. Only the 
DPP Biguanide medication class showed an R2 value of any significance at 5%. 
Additional covariates would only give us the covariates' effect and not by HbA1c or 
PDC, our predictors of concern.  No collinearity was present with a VIF value of 1.150 
for all of the regressions performed. 
Table 27  
 
















1 .055a 0.003 0.003 0.99438 
a. Predictors: (Constant), Adj LIS, 
DSNP_INDICATOR 
 
Table 28  
 


















Constant 6.650 0.010 
 
682.504 0.000 6.631 6.670 
DSNP -0.126 0.015 -0.059 -8.313 0.000 -0.156 -0.097 
LIS -0.050 0.017 -0.021 -2.916 0.004 -0.084 -0.016 
a. Dependent Variable: HbA1c level 
 
Table 29  
 
Regression Analysis for Each of the Medication Classes PDC Values.  
 
        
95.0% 
Confidence 








B Sig Lower Upper 
VIF 
Biguanides 0.008     
 
DSNP  -0.030 0.000 -0.036 -0.024 1.150 
LIS  -0.033 0.000 -0.040 -0.026 1.150 
DPP 0.071     
 
DSNP  0.148 0.000 0.112 0.184 1.150 
LIS  0.124 0.000 0.084 0.163 1.150 
Thiazolidinediones 0.001     
 
DSNP  -0.14 0.564 -0.06 0.033 1.150 





Sulfonylureas 0.007     
 
DSNP  -0.033 0.000 -0.047 -0.200 1.150 
LIS  -0.023 0.002 -0.038 -0.009 1.150 
Sulfonylurea-Biguanide  0.001     
 
DSNP  -0.028 0.165 -0.069 0.012 1.150 
LIS  -0.024 0.261 -0.066 0.018 1.150 
DPP Biguanide 0.050     
 
DSNP  0.107 0.000 0.065 0.149 1.150 





Our analysis indicates that while the DSNP and LIS financial subsidy programs 
have statistically significant effects on HbA1c and medication compliance measured by 
the PDC, they have a minimal overall effect on these measures with R2 values below 1%. 
Our analysis demonstrates that both research questions' null hypothesis can be accepted 
and that there is no significant relationship between these subsidy programs and either 
PDC or HbA1c levels. Our results are the same as those of a 2012 study in that we found 
little difference in medication compliance based on MPR, whether an individual was in a 
LIS subsidy program or not, and even where there were differences, those differences 
were of little clinical significance (Stuart et al., 2012).    
CMS implemented these plans to help participants by reducing their financial 
burden from deductibles and copays, particularly the LIS program which is designed 
solely for this purpose. The DSNP program covers more than just medication costs. Our 
primary findings indicate that participation in either a LIS or DSNP program does not 





levels. However, caution should be used in interpreting these results. Because of our large 
sample size, one would expect to see statistical significance in the predictors. However, 
there is little clinical significance in these programs, as demonstrated by the minimal R2 
values.  
Limitations of the Study 
The results of this analysis of financial subsidy programs can only be applied to 
people with diabetes and not to other chronic conditions.  Additionally, there are 
difficulties in relating PDC values to someone actually consuming a medication as 
directed. In this study we have to assumed that purchased medications are equal to 
consumed medications. Smaller sample size research that closely monitors HbA1c levels 
and PDC are needed to examine the effects of these subsidy programs on other 
morbidities. It was beyond the scope of this study to examine whether increased subsidies 
would positively impact compliance and reduce HbA1c levels, and further research is 
needed to clarify these issues.  Finally, because we examined only members who took 
one of the medication classes, there may be positive effects for those taking more than 
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 Cardiovascular disease is the number one killer of Americans, and one-third of 
blindness worldwide is related to diabetes. However, less than one-third of people with 
diabetes are compliant with their antibiotic therapy treating a UTI, and diabetes is the 
most common cause of end-stage renal disease in the US.  Medication is a primary 
therapeutic modality in the treatment of diabetes that reduces the incidence of these 
comorbidities, yet compliance rates are as low as 50%. The Proportion of Days Covered 
(PDC) is the accepted method for determining medication compliance. The purpose of 
this study is to determine the associations between antihyperglycemic medication class 
PDC rates and HbA1c levels and four of the diabetes comorbidities, vision impairment, 
renal disease, myocardial infarction, and urinary tract infections. A sample of 22,000 
adults over 21 years of age, who took only one of six oral antihyperglycemic medication 
classes, had an HbA1c reported during the year, and diagnosed with type 2 diabetes were 
selected from the 2019 claims database of a large MCO. There are statistically significant 
relationships between HbA1c, compliance, and comorbidities but, the highest strength of 
effect found was 0.5%. It may indicate a need to look at different predictors such as those 
related to the Social Determinants of Health, none of which were included. These results 








Thirty-four million Americans are diagnosed with diabetes, and another 88 
million have pre-diabetes. Many pre-diabetic individuals do not know they have the 
disease (Centers for Disease Control and Prevention, 2020; National Institute of Diabetes 
and Digestive and Kidney Diseases, 2017). The Center for Disease Control (CDC) has 
undertaken programs to address the issue of prediabetes diagnosis by Primary Care 
Providers (PCP) (Li et al., 2013). In 2017, Tseng et al. found that only six percent of 
PCP’s recognized all the risk factors that should initiate a prediabetes screening, and only 
17% correctly identified the laboratory parameters for diagnosing prediabetes. Twenty 
percent of all U.S. healthcare costs can be related to the treatment of diabetes and its 
complications, and diabetes is the seventh leading cause of death in the US (National 
Center for Chronic Disease Prevention, 2016).  
Effective management of people with type 2 diabetes includes supporting efforts 
that improve medication compliance. The comorbidities of diabetes result from micro and 
macrovascular changes leading to reduced health statuses. Macrovascular complications 
include congestive heart failure, myocardial infarction, stroke, and coronary artery 
disease. Microvascular complications include neuropathy, retinopathy, and nephropathy. 
One person dies every 37 seconds from cardiovascular disease which is the leading killer 
in the United States. (Heron, 2017).  Hyperglycemia induces the formation of glycated 
end products, the production of oxygenated free radicals, and increased rates of 





comorbidity risks in people with diabetes increase as HbA1c levels increase, so 
consistent control of HbA1c levels is imperative for comorbidity control (Luo et al., 
2017).  
Diabetic retinopathy is the most common microvascular complication of diabetes 
(Antonetti et al., 2012). Across the world, one-third of people with diabetes are affected 
by retinopathy, a leading cause of vision loss in 20 to 74-year-olds. Risk factors for 
retinopathy include duration of diabetes, HbA1c levels, and blood pressure control 
(Solomon et al., 2017; Yau et al., 2012). Progression of retinopathies at four to six years 
post-diagnosis range from 24.1% to 38.9% and increase to 64.1% and 83.1 % in 16-year 
and 25-year follow-ups (Lee et al., 2015). 
 Diabetes is the most common cause of end-stage renal disease (ESRD) in the US. 
Due to the increased longevity in people with diabetes, comorbidity rates are increasing, 
and those diagnosed with ESRD are accepted in treatment centers where they have not 
been in the past (Molitch et al., 2004). Twenty to forty percent of all people with diabetes 
develop some nephropathy, yet it rarely develops in people with type 1 diabetes within 
the first ten years of diagnosis (Gall et al., 1991). Annual albuminuria screenings are 
recommended for all people with diabetes.  
The risk of Urinary Tract Infections increases with age, poor HbA1 control, 
immune system compromise, and poor bladder emptying due to neuropathies. Those who 
have diabetes have a higher incidence of UTI’s and the infections they get are more 





cases, UTIs can lead to death due to pyelonephritis (Saleem & Daniel, 2011).  UTI’s have 
been traced to the neuropathies associated with diabetes (Brown et al., 2005).  Less than 
35% of those with diabetes and a UTI are compliant with their antibiotic therapies and 
UTIs can increase total health care costs by 53% (Davis-Ajami et al., 2019).  
Medication compliance in those with diabetes is an essential part of their therapy. 
However, in those diagnosed with diabetes, compliance rates fall around 50% (Wang et 
al., 2013). Forty-five percent of diabetics fail to achieve adequate HbA1c or blood sugar 
control (Polonsky & Henry, 2016). Medication compliance is the best way to reduce the 
risks of diabetes complications (Nichols et al., 2016). Because of the multiple 
complications of diabetes, polypharmacy is common and presents additional problems for 
providers. The incidence of noncompliance related to medication cost is 16% and is the 
second most common reason for non-compliance in people with diabetes. The Social 
Determinants of Health, medication packaging, poor communication skills, low health 
literacy levels, a lack of trust in providers, and belief that the medications they are 
prescribed do not help their diabetes all contribute to poor HbA1c and glucose level 
control (Gilmartin-Thomas et al., 2017; Pruitt et al., 2018; Shiyanbola et al., 2018).   
The currently accepted method of calculating medication compliance is using the 
Proportion of Days Covered (PDC).  The CDC adopted the PDC as the recommended 
medication compliance methodology for researchers in 2015 with the PDC supported by 
the Pharmacy Quality Alliance and CMS and is the leading method for determining 





NCQA has accepted the PDC method of measuring medication compliance in their 
HEDIS measures. Medications used in treating type 2 diabetes are separated into nine 
classes based on their mechanism of action (Feingold, 2019). Only six of these classes, 
both as individual classes and commercially available combinations of classes are 
analyzed in this study  To date, there is little in the literature studying the relationship 
between classes of antihyperglycemic medications, HbA1c levels, and comorbidities. 
One purpose of this study is to examine relationships between various classes of 
antihyperglycemic medications, compliance with these medications, and the 
comorbidities of diabetes.  
Research Design and Methods 
When a researcher wants to establish the relationships between variables, a 
quantitative approach is appropriate (Creswell & Creswell, 2017). The purpose of this 
study is to examine the relationships between antihyperglycemic medications, HbA1c 
levels, the PDC and the comorbidities of diabetes, Myocardial Infarction, Blindness, End-
Stage Renal Disease, and Urinary Tract infections and a set of covariates including age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County as defined by the Census Bureau. The 
research questions for this manuscript are: 
RQ5: Is there a relationship between the PDC calculated for individual 
antihyperglycemic class of medications and HbA1c values on the top four type 2 diabetes 





Tract infections, both individually and in combination, in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County as defined by the 
Census Bureau. 
H025: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the top 
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness, 
End-Stage Renal Disease, and Urinary Tract infections while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H125: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the top 
four Medicare type 2 diabetes comorbidities of Myocardial Infarction, Blindness, 
End-Stage Renal Disease, and Urinary Tract infections while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County.  
H026: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of 
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 





MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H126: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the top four Medicare type 2 diabetes comorbidities of 
Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 
infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County.  
H027: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H127: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 





H028: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylureas class of medications and the top four Medicare 
type 2 diabetes comorbidities of Myocardial Infarction, Blindness, End-Stage 
Renal Disease, and Urinary Tract infections and HbA1c values while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H128: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylureas class of medications and HbA1c values and the 
top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County.  
H029: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the top four Medicare type 2 diabetes comorbidities of Myocardial Infarction, 
Blindness, End-Stage Renal Disease, and Urinary Tract infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H129: There is a statistically significant relationship between the PDC index 
calculated for the individual Meglitinide Analogues class of medications and 





Myocardial Infarction, Blindness, End-Stage Renal Disease, and Urinary Tract 
infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County.  
H030: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the top four Medicare type 2 diabetes 
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and 
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H130: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the top four Medicare type 2 diabetes 
comorbidities of Myocardial Infarction, Blindness, End-Stage Renal Disease, and 
Urinary Tract infections while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County.  
H031: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H131: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Myocardial Infarction while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H032: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial 
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H132: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Myocardial 
Infarction while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H033: There is no statistically significant relationship between the PDC index 





the Medicare type 2 diabetes comorbidity of Myocardial Infarction while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H133: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Myocardial Infarction while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H034: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
comorbidity of Myocardial Infarction in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H134: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and the comorbidity of 
Myocardial Infarction and HbA1c values in Medicare type 2 diabetics while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H035: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H135: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Myocardial Infarction in type 2 diabetics while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H036: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Myocardial Infarction in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H136: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Myocardial Infarction in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H037: There is no statistically significant relationship between the PDC index 





Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H137: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H038: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H138: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Blindness 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 






H039: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H139: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Blindness while controlling for age, 
sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, 
DSNP enrollment, and living in Urban or Rural County. 
H040: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 
enrollment, and living in Urban or Rural County. 
H140: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Blindness while controlling for age, sex, 
diabetes diagnosis time, length of time in MCO, Plan type, LIS enrollment, DSNP 





H041: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of Blindness while controlling for 
age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H141: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Blindness in Medicare type 2 diabetics while controlling 
for age, sex, diabetes diagnosis time, length of time in MCO, Plan type, LIS 
enrollment, DSNP enrollment, and living in Urban or Rural County. 
H042: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Blindness in Medicare 
type 2 diabetics while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H142: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Blindness in Medicare 





time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H043: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H143: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H044: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of End-Stage 
Renal Disease while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H144: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 





Renal Disease while controlling for age, sex, diabetes diagnosis time, length of 
time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban 
or Rural County. 
H045: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H145: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H046: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H146: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 





controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H047: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of End-Stage Renal Disease while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H147: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of End-Stage Renal Disease in Medicare type 2 diabetics 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H048: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of End-Stage Renal Disease 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and 
living in Urban or Rural County. 
H148: There is a statistically significant relationship between the PDC index 





medications and HbA1c values and the comorbidity of End-Stage Renal Disease 
in Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis 
time, length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and 
living in Urban or Rural County. 
H049: There is no statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H149: There is a statistically significant relationship between the PDC index 
calculated for the Biguanides class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H050: There is no statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract 
Infections while controlling for age, sex, diabetes diagnosis time, length of time in 






H150: There is a statistically significant relationship between the PDC index 
calculated for the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors class of medications 
and HbA1c values and the Medicare type 2 diabetes comorbidity of Urinary Tract 
Infections while controlling for age, sex, diabetes diagnosis time, length of time in 
MCO, Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H051: There is no statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H151: There is a statistically significant relationship between the PDC index 
calculated for the Thiazolidinedione class of medications and HbA1c values and 
the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H052: There is no statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 





H152: There is a statistically significant relationship between the PDC index 
calculated for the Sulfonylurea class of medications and HbA1c values and the 
Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H053: There is no statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the Medicare type 2 diabetes comorbidity of Urinary Tract Infections while 
controlling for age, sex, diabetes diagnosis time, length of time in MCO, Plan 
type, LIS enrollment, DSNP enrollment, and living in Urban or Rural County. 
H153: There is a statistically significant relationship between the PDC index 
calculated for the Meglitinide Analogues class of medications and HbA1c values 
and the comorbidity of Urinary Tract Infections in Medicare type 2 diabetics 
while controlling for age, sex, diabetes diagnosis time, length of time in MCO, 
Plan type, LIS enrollment, DSNP enrollment, and living in Urban or Rural 
County. 
H054: There is no statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Urinary Tract Infections in 





length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
H154: There is a statistically significant relationship between the PDC index 
calculated for the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors class of 
medications and HbA1c values and the comorbidity of Urinary Tract Infections in 
Medicare type 2 diabetics while controlling for age, sex, diabetes diagnosis time, 
length of time in MCO, Plan type, LIS enrollment, DSNP enrollment, and living 
in Urban or Rural County. 
This is a quantitative longitudinal retrospective study using 2019 secondary 
claims data from a large nationwide MCO. According to Creswell (2017), a longitudinal 
study is appropriate when a researcher is looking for relationships between predictor and 
outcome variables. This longitudinal retrospective study examines the relationships 
between the comorbidities of diabetes, medication compliance with antihyperglycemic 
medications, and HbA1c levels as predictors, along with multiple covariates. The study 
population is approximately 23,000 are over 21, currently diagnosed with type 2 diabetes, 
enrolled in either a Medicare Advantage (MA) plan during the 2019 calendar year, had an 
HbA1c level done during 2019, and took only one of the six classes of antihyperglycemic 
medications or a combination of classes. 
All the data provided by the MCO were deidentified before release to the 
researcher. Each member is assigned a unique serial number that was included with the 





can be mapped back to individual members using the serial number assigned. Using 
G*Power, version 3.1.9.4, an effect size of 0.15, an alpha error probability of 0.05, a 
power of 0.95, the recommended sample size is 89. In a meta-analysis of medication 
compliance studies with different diseases, the authors found that studies with more than 
85 participants had high statistical power. The authors also found that effect sizes in the 
studies reviewed was 0.17 to 0.18 with P < 0.0001. Based on this meta-study, we chose a 
value of 0.15 (Foot et al., 2016). G* Power's effect size is a method to quantify the 
differences between the test and control groups and is based on Cohen’s effect size or the 
explained variance and error variance (Cunningham & McCrum-Gardner, 2007).  With 
23,000 participants, this study has more than sufficient participants to achieve statistical 
power. The entire sample population will be used for each research question. We 
excluded individuals who may have taken more than one medication class because we 
cannot associate an HbA1c level with multiple medications.  
 The ICD-10 World Health Organization International Statistical Classification of 
Diseases and Related Health Problems is used to determine a diagnosis of diabetes. We 
will use the ICD-10 code of E11.9 for this data pull. Pharmacy records were pulled from 
claims data, and demographic data came from other in-house databases. The medication 
start date will be the date of the first dispensing of an antihyperglycemic medication. 
Members are split between a learning group, L1, and a holdout group, HO1, which is 





 Income and asset levels are implied from participation in either a Low-Income 
Subsidy (LIS) or a Dually Eligible Special Needs Program (DSNP) program. The 
eligibility requirements for DSNP plans are that income levels be less than the poverty 
level. For enrollment in a LIS program, income levels must be between the poverty level 
and 300% of the poverty level. We created a categorical variable with three items 
indicating the three different income levels of our participants. The third level is those not 
in one of these programs with an income above 300% of the poverty level.  
Analysis of the data was conducted using SPSS version 27 with a standard p-
value of < 0.05 to indicate statistical significance. Logistic regression analysis was used 
to determine the effect each of the predictors on the outcome variable, and we can us 
statistical significance to determine which of the variables are predictive of an outcome 
(Warner, 2013).  Logistic regressions are used to explain relationships between a binary 
outcome variable, in this case, comorbidities of diabetes, and ordinal, nominal, or ratio 
predictor variables (Wagner, 2016). For logistic regression, the outcome variable must be 
binary, so we used binary variables in defining the comorbidities of interest.  
The sample was split into learning groups and testing groups for each of the 
research questions. The sample was split with 70% to the learning group and 30% to the 
testing group (Pang & Jung, 2013). Predictions will be made on each testing group model 
and then run a Chi-Square test on the actual comorbidities’ incidence and the predicted 





In running regressions, caution is necessary, and collinearity must be examined. 
In regression analysis, each predictor variable must represent a unique effect on the 
outcome variable. When two or more predictors conflict and have the same effect on the 
outcome variable, collinearity is present.  We addressed collinearity using the SPSS 
bivariate correlation function where a positive collinearity absolute value greater than 0.8 
indicates collinearity. Additionally, we included the collinearity diagnostics in the 
regression analysis using a VIF value greater than 10 to indicate a collinearity problem.  
Table 30  
Predictor Variables, their type, and possible values 
 
Variable Name Variable Type Possible Values 
Unique member identifier. Nominal Format TBD by MCO 
Age Continuous 21-100 
Sex Categorical 0=male, 
1=female 
HBA1c level  Continuous actual level 
Seeing an Endocrinologist  Categorical  0=no, 1=yes 
Medication Class Ordinal 1-35 
Medication PDC Continuous 0-1 
Deductible Continuous $0 - $415 
Had Myocardial Infraction  Nominal 0=no, 1=yes. 
Is Blind  Nominal 0=no, 1=yes. 
Has End-Stage Renal Disease Nominal 0=no, 1=yes. 
Has Urinary Tract infections Nominal 0=no, 1=yes. 
LIS enrollment   Continuous 0=no, 1=yes 
Dual enrollment Continuous 0=no, 1=yes 
 
Each of these predictive model equations was determined by picking the 
predictors where their p-value is < 0.05. The equations for each of the research questions 





the HbA1c value, b is the y-axis intercept, and m is the coefficient for a statistically 
significant predictor variable. The final equation will take the final form of y = b + 
coeff1*predictor1 value + coeff2*predictor2 value + coeff3*predictor3 value + 
coeffN*predictorN value. This final equation will define the model for predicting either 
renal or retinal screening participation. The direction and strength of a linear relationship 
between two variables can be determined by Pearson’s correlation (Warner, 2013). 
Values greater than 0.5 show significant levels of correlation between the variables. 
Values approaching 0.3 have small correlations but still significant enough to consider in 
the final equation. Any predictor variable used must have a p-value of less than 0.05. 
Pearson’s correlations can give us some insight into the R2 value produced by regression 
analysis because it gives us a feeling for the strength of effect (Warner, 2013). Pearson’s 
correlation values are obtained by selecting a correlation from the SPSS interface and 
adding all of the analysis variables. 
R2 is a statistical value created by a regression analysis indicating how well the 
predictor variables match the regression line (Warner, 2013).  The models' R2 value 
indicates the quality of the data's fit to the line created by the regression. In human 
research, an R2 value greater than 0.2 is considered adequate. This value is somewhat 
lower than in other kinds of research, but because human behavior is included in the 
analysis, this lower number is acceptable (Hair et al., 2011). Plots of the data are 
necessary to determine bias in the data. If the data is evenly dispersed around the 





non-linear approach is better (Warner, 2013). An analysis of Pearson’s and the R2 value 
will be conducted in the same manner as for the learning group.  
Results 
 The purpose of this study is to determine what relationships exist between four of 
the comorbidities of type 2 diabetes, myocardial infarction, renal disease, blindness, and 
urinary tract infections, and HbA1c, medication class, and the PDC value. Our original 
sample size was 37,363. We removed those who did not have an HbA1c level reported 
for 2019, leaving a final sample size of 22,638. We then split this into a learning group of 
15,845 and a testing group of 6,793. Table 31 is a list of predictors available in the data 
and the count for each. Because the regression analysis requires that each predictor 
entered have a value, many of our regressions either had no cases or too few for statistical 
power.  
Table 31  






Sulfonylurea Biguanide 228 
DPP Biguanide 367 
Male 6482 
Female 9363 
DSNP Plan 5151 
LIS Plan 3432 
No Subsidy 7262 





Retinopathy screening 1639 
Nephropathy screening 3346 
Controlled Blood Pressure 5896 
  
We ran individual binary logistic regressions, using SPSS version 27, with end-
stage renal disease, blindness, myocardial infarction, and UTI as the outcome variables, 
and each of the medication class PDC’s as the predictor variables. Table 32 shows the 
outcome of those regressions for each of the comorbidities and each of the means 
adjusted medication class PDC values. We then removed the models that did not show 
any statistical significance and where we had case counts less than 89, as number derived 
by G*Power.   
For many of the regressions that included all of our predictors, we could not get 
enough cases to complete a regression analysis. Table 32 show the results of running 
additional regressions where we could get enough cases.  
Table 32  
 
Binary Regression of Comorbidity and Medication PDC values 
 
Outcome 






(1) Sig Exp(B) 
Renal Disease Total PDC 0.000 3681 0.000 1.556 
 Biguanide 0.001 2113 0.001 1.592 
 DPP 0.460 260 0.460 0.745 
 Thiazolidinediones 0.942 80 0.942 1.060 
 Sulfonylurea 0.018 1048 0.019 1.728 
 
Sulfonylurea 
Biguanide 0.141 44 0.170 6.381 





Blindness Total PDC 0.565 207 0.569 1.259 
 Biguanide 0.583 140 0.858 1.312 
 DPP 0.020 11 0.014 0.059 
 Thiazolidinediones 0.536 6 0.514 0.278 
 Sulfonylurea 0.007 39 0.025 30.346 
 
Sulfonylurea 
Biguanide 0.538 5 0.581 9.064 
 DPP Biguanide 0.346 2 0.454 126.53 
Myocardial 
Infarction Total PDC 0.009 1007 0.008 0.631 
 Biguanide 0.114 648 0.110 0.703 
 DPP 0.004 59 0.003 0.180 
 Thiazolidinediones 0.266 11 0.239 0.186 
 Sulfonylurea 0.776 248 0.775 0.898 
 
Sulfonylurea 
Biguanide 0.645 12 0.633 0.433 
 DPP Biguanide 0.427 17 0.446 2.849 
UTI Total PDC 0.778 2460 0.778 0.968 
 Biguanide 0.909 1735 0.909 0.983 
 DPP 0.453 128 0.449 0.700 
 Thiazolidinediones 0.412 35 0.402 0.444 
 Sulfonylurea 0.874 460 0.875 1.048 
 
Sulfonylurea 
Biguanide 0.065 28 0.107 23.059 
 DPP Biguanide 0.267 48 0.258 0.445 
 
Table 33  
 















Total PDC 0.000 3529 0.183 0.109 1.201 
 Age 
  0.059 0.000 1.060 
 Deductible 






  0.026 0.623 1.027 
 DSNP 
  0.628 0.000 1.874 
 HbA1c Level 
  -0.200 0.332 0.980 
 Seeing Endocrinologist   0.043 0.116 1.044 
 Hospital Visits   0.055 0.116 1.056 
 Retinopathy Screening   -0.161 0.183 0.851 
 Nephropathy Screening   0.111 0.187 1.118 
 Gender (F reference) 
  0.226 0.000 1.254 
 Biguanide PDC 0.000 2103 0.163 0.271 1.117 
 Age 
  0.052 0.000 1.053 
 Deductible 
  -0.002 0.000 0.998 
 LIS 
  0.004 0.955 1.004 
 DSNP 
  0.599 0.000 1.820 
 Gender (F reference) 
  0.136 0.007 1.146 
 HbA1c Level 
  -0.029 0.318 0.971 
 Seeing Endocrinologist   0.086 0.005 1.089 
 Hospital Visits   0.027 0.000 1.027 
 Retinopathy Screening   0.109 0.176 1.115 
 Nephropathy Screening   0.511 0.000 1.667 
 Constant 
  -5.269 0.000 0.005 
 Sulfonylurea PDC 0.000 677 0.405 0.000 0.030 
 Age 
  0.490 0.000 1.051 
 Deductible 
  -0.002 0.000 0.998 
 LIS 
  -0.030 0.795 0.971 
 DSNP 
  0.590 0.005 1.804 
 HbA1c Level 
  -0.111 0.003 0.895 
 Seeing Endocrinologist   -0.026 0.533 0.974 
 Hospital Visits   0.041 0.000 1.042 
 Retinopathy Screening   0.091 0.543 1.095 
 Nephropathy Screening   0.371 0.001 1.449 
 Gender (F reference) 
  0.344 0.000 1.410 
Myocardial 
Infarction 
Total PDC 0.000 1003 -0.479 0.008 0.620 
 Age 
  0.024 0.000 1.025 
 Deductible 
  -0.001 0.100 0.999 
 LIS 
  0.067 0.458 1.069 
 DSNP 





 Gender (F reference) 
  0.698 0.000 2.009 
 Seeing Endocrinologist   0.043 0.116 1.044 
 Hospital Visits   0.055 0.116 1.056 
 Retinopathy Screening   -0.161 0.183 0.851 
 Nephropathy Screening   0.111 0.187 1.118 
 HbA1c Level   0.006 0.849 1.006 
  Constant     -4.9360 0.000 0.007 
 
Discussion 
 HbA1c levels consistently show no statistical significance related to the four 
comorbidities examined here, UTI, MI, blindness, and renal disease. These findings are 
not what we expected, nor what has been published in the literature (Luo et al., 2017). 
The discrepancy could be related to our lack of understanding of the relationship between 
comorbid diagnosis date and when HbA1c levels were drawn, and when the comorbid 
diagnosis was made. Additionally, we do not have HbA1c levels over time.   
The analysis showed that being in a DSNP program doubles the chances of renal 
disease compared to those not in a financial subsidy program while controlling for 
covariates. However, this is not surprising, as ESRD is one of the diagnoses needed for 
eligibility into a DSNP program.  We also found that males have a two times greater 
chance of having an MI than females when controlling for the other covariates, matching 
the literature, where women generally have heart attacks 7 to 10 years later than males 
(Liakos & Parikh, 2018; Maas & Appelman, 2010).  However, we did not see any 





females in the study than males who may have contributed to females having a greater 
risk of MI than males in our data.  
Table 34  
 
Mean Age by Gender 
 
Gender Mean N Composition Std. Deviation 
Female 71.30 9363 59% 9.470 
Male 70.59 6482 41% 9.414 
Total 71.01 15845  9.453 
 
 Our analysis did not uncover any significant relationships other than what has 
been found in previously published studies (however, these studies were not looking at 
specific comorbidities of diabetes).  We did not have enough members with comorbidity 
and covariates to do as complete an analysis as we wanted, nor were we able to develop 
any predictive models for the same reason. We did have enough members to find the R2 
values to be so low as to render our models insignificant.  
Limitations and Future Areas for Study 
 There are several limitations to this study related to the comorbidities of type 2 
diabetes. Our data did not give the length of time since any of the comorbidities were 
diagnosed. Our data did not provide when HbA1c levels were completed, which may 
have affected our results. Additionally, we are not able to relate HbA1c levels to 
comorbidities.  
The insignificance of our R2 values, where we could get one, indicates that we are 





area of future study would be to look at how the SDOH impact the four comorbidities 
examine here. There is evidence for the relationship between the SDOH and diabetes 
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Part 3 : Summary 
Introduction 
The first of the three studies presented here examined the relationship between 
medication compliance in six of the antihyperglycemic medication classes and HbA1c 
levels in people with type 2 diabetes. The second study examined the effectiveness of 
financial subsidies on medication compliance and HbA1c levels in people with type 2 
diabetes. The third study examined the relationship between the comorbidities of type 2 
diabetes and medication compliance.  The individuals in all these studies came from a 
large, nationwide MCO, have a diagnosis of type 2 diabetes, were taking one of six 
medication classes of antihyperglycemic medications, or a combination of them, took 
only one of these during the year, and had at least one HbA1c level done during the year. 
Participants were chosen from the claims database of a large, national MCO from 2019.  
Of the original 56,000 potential MCO members for this study, final counts varied from 
22,000 to 15,000, depending on the study. All studies have sufficient members to achieve 
statistical power.  
 The study results demonstrate clinically significant findings in the relationship 
between medication compliance and the medication a person with diabetes consumes. It 
shows that practitioners should consider how compliant their patient is when considering 
a medication regimen.  In part, Medicare created the LIS and DSNP programs to improve 
medication compliance by reducing copays and deductibles.  Study two demonstrated 





levels, the ultimate goal of therapy. Finally, the third study was unable to establish any 
relationships between four of the comorbidities of diabetes and medication compliance in 
people with type 2 diabetes.  
Summary of Findings 
 Study one demonstrated that medication compliance should be a factor when 
providers decide which medications they are going to use to treat their patients.  We 
found that the Sulfonylurea-Biguanide combination, slope1 = -2.49, is most sensitive to 
compliance, demonstrating that the Sulfonylurea-Biguanide class of medications should 
be avoided in patients providers feel, or will be, non-compliant. However, the DPP class 
of medications, slope =  -0.09, Biguanide class, slope = -0.16, and Sulfonylurea class, 
slope = -0.25, are the least affected by medication compliance.  Thiazolidinediones, slope 
= -0.83, and DPP-Biguanides, slope = -0.94, are moderately affected by medication 
compliance compared to the other classes discussed here. Finally, we demonstrate that 
with compliance rates above 85%, each of these medication classes' effectiveness is 
similar.  
 In part, Medicare instituted the LIS and DSNP programs that reduce copays and 
deductibles to improve medication compliance and in people with diabetes, thereby 
reducing HbA1c levels. While we had statistically significant findings that these 
programs affect compliance and HbA1c levels, the R2 values were all less than 1%, 
                                                 
1 Slope is for each unit increase in PCD, HbA1c changes by slope value units. Slopes are 





indicating that their effect is insignificant. Our findings are similar to another study 
conducted in 2012 that used the MPR compliance method and not the PDC method for 
calculating compliance as used in this study.  
 Our third study examined the relationship between HbA1c levels and four of the 
comorbidities of diabetes, UTIs, MI’s, ESRD, and blindness. Our findings conflict with 
the published literature, but our evidence is conflicting.  For example, those in a DSNP 
program showed double the chance of having renal disease when compared to those not 
getting financial assistance. However, having an ESRD diagnosis is one of the predicates 
of being in a DSNP program, and we did not have diagnosis dates to include in our 
analysis. We did find that males had two times greater chance than females of having an 
MI, and we did not find any differences when examing age.   
Interpretation of Findings 
 In our study of the relationship between HbA1c and medication compliance, we 
found a statistically significant relationship. This study's findings reveal that during the 
clinical medication therapy decision-making process for people with type 2 diabetes, 
providers should consider how compliant their patients are in taking their medications 
and considering the medication class to prescribe. Most significantly, we found that the 
Sulfonylurea-Biguanide combination should be reserved for patients who will be more 
than 85% compliant to maintain acceptable HbA1c levels. We also found that the DPP, 





so these would be good therapy choices for patients that providers feel will be non-
compliance in taking their medications.  
 In examining the LIS and DSNP program's effects on medication compliance and 
HbA1c levels, we found that while there is a statistically significant relationship, these 
relationships' strength is minimal at best (R2 < 1%).  The purpose of these programs is to 
help reduce the financial burdens that may lead to medication non-compliance. However, 
the evidence does not support this.  
 Our final study found little evidence establishing a relationship between UTIs, 
MI’s, blindness, or ESRD.  Our findings in this study were unexpected as it is not 
consistent with past studies on the comorbidities of diabetes. However, these studies did 
not look specifically at medication compliance and these comorbidities. There could be 
several explanations for this discrepancy. First, this is not a long-term study, there are 
other factors than what we looked at that contribute to the comorbidities, and we only had 
a single HbA1c level taken during one year.  
Limitations of Study 
 We identified several limitations for all these studies.  We could not associate the 
date an HbA1 level was obtained and medication compliance rates, possibly skewing our 
results. We found statistically significant relationships that the R2 values were low with 
values less than 5%.  We did not have access to the social determinant of health data at a 
member level. We tried a multilevel analysis at a zip code level but did not get any 





studies, further studies need to examine how the social determinant of health fit into the 
relationships between medication compliance and HbA1c and the comorbidities of 
diabetes. While we found indications of strong relationships between medication class 
and HbA1c levels, smaller studies are needed where compliance and medication class can 
be more closely associated with HbA1c levels.  Finally, we only looked at people with 
diabetes who took a single medication during 2019. People with diabetes are also on 
multiple medications during the year or switched from one medication to another. These 
cases are also deserving of closer scrutiny with more closely controlled studies 
Individual 
 Eighty-five million Americans have been diagnosed with diabetes, and another 30 
million have been diagnosed with pre-diabetes, constituting one-third of the country's 
population. Diabetes costs the US hundreds of billions of dollars in medical costs each 
year and is one of the most prominent US's chronic diseases. Medication therapy is a 
crucial component for a person with diabetes, and compliance with their medications is 
the primary component of that regimen.  These studies provide new evidence for 
practitioners when making therapy decisions showing them that not only is the class of 
medication selected essential but that the compliance level of their patient must be just as 
important a factor in medication selection.  Additionally, the studies show that the 
Medicare financial incentive program aimed at improving compliance is not having the 







 Primarily related to practitioners is study one. This study provides evidence on the 
importance of compliance when instituting a medication therapy plan.  We showed that 
the ability of different medications to control HbA1c levels is statistically related to how 
compliant their patient will be.  We showed that some medication classes are susceptible 
to compliance, and others a not affected much by compliance rates. We showed that for 
compliant patients (over 80% of the time), there is not much difference in the effect of 
compliance on HbA1c control. Provider medication decisions are essential in finding 
ways to control their patients' blood sugar levels. Controlled blood sugars result in lower 
societal medication costs, better health statuses, and lowered diabetes complications for 
people who have diabetes.  
Societal 
The societal costs from diabetes are significant including financial, burdens on the 
healthcare system and the effects of poor health statuses of people with diabetes. The 
financial costs are borne by insurers, payors, and those without insurance individuals.  
Lost work productivity contributes to the financial costs of diabetes, and for those 
without sick, benefits may add to lowered health statuses.  
We found that Medicare’s financial programs aimed at improving compliance rates are 
not having the desired effect.  We demonstrated that a reevaluation of these programs 





contribute to improved compliance or lowered HbA1c levels as designed, and there 
should be consideration for allocating these resources differently.   
Implications for Social Change 
Individual 
Eighty-five million Americans have been diagnosed with diabetes, and another 30 million 
have been diagnosed with pre-diabetes constituting one-third of the country's population. 
Diabetes costs the US hundreds of billions of dollars in medical costs each year and is 
one of the most prominent US chronic diseases. Medication therapy is a crucial 
component for a person with diabetes, and compliance with their medications is the 
primary component of that regimen.  These studies provide new evidence for 
practitioners when making therapy decisions showing them that not only is the class of 
medication selected essential but that the compliance level of their patient must be just as 
important a factor in medication selection.  Additionally, the studies show that the 
Medicare financial incentive program aimed at improving compliance is not having the 
desired impact and the need for future studies of the LIS and DSNP (pharmacy part) 
programs.  
Clinical 
 Primarily related to practitioners is study one. This study provides evidence on the 
importance of compliance when instituting a medication therapy plan.  We showed that 
different medications' ability to control HbA1c levels is statistically related to how 





to compliance, and others a not affected much by compliance rates. We also showed that 
across patients compliant with their medications (over 80% of the time), there is not 
much difference in HbA1c control based on different medications. These decisions are 
essential in provider’s efforts in finding ways to control their patients' blood sugar levels. 
Controlled blood sugars result in lower societal medication costs, better health statuses, 
and lowered diabetes complications for people who have diabetes.  
Societal 
The societal costs from diabetes are significant including financial, burdens on the 
healthcare system and the effects of poor health statuses of people with diabetes. 
Financial costs fall on insurers, payors, and those individuals without insurance.  Lost 
work productivity contributes to the financial costs of diabetes, and for those without 
sick, benefits may add to lowered health statuses.  
We found that Medicare’s financial programs aimed at improving compliance 
rates are not having the desired effect.  We demonstrated that a reevaluation of these 
programs should be considered, and new approaches are needed. These financial 
programs do not contribute to improved compliance or lowered HbA1c levels as 
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